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INTRODUCTION
More than 40 million people worldwide are infected with HIV/AIDS, 
and more than 3.1 million AIDS-related deaths occurred worldwide each 
year. In India, there is an estimated 5.1 million people infected with HIV 
today1. Current anti-HIV drug therapy has made a tremendous difference 
in  the  lives  of  many people  with  HIV  infection.  Unfortunately,  the  life-
extending benefits of anti-HIV drug treatment have opened up a new set 
of problems for many HIV positive people, coinfected with other viruses2.
Hepatic  abnormalities  are  quite  common  among  HIV  infected 
persons.  Thousands of  people with  HIV are also infected,  or  at  risk of 
being infected with one of the several hepatitis viruses. Some of these 
viruses can cause  chronic infection which  may result  in  cirrhosis,  liver 
failure,  and hepatocellular  carcinoma in  a  proportion of  patients.  Apart 
from being more prevalent, the natural history of these hepatitis viruses 
may  be  modified  in  patients  with  HIV  infection  and  hence  their 
significance3.  Also  it  has  been  claimed  that  certain  hepatitis  virus 
infections  may  exacerbate  the  course  of  HIV  infection,  with  rapid 
progression  to  AIDS,  although  this  observation  has  not  yet  been 
confirmed.
Viral hepatitis is not so much an opportunistic infection in patients 
with  HIV  infection,   as  it  is  companion  infection.  Thus  because  some 
forms  of  hepatitis  are  acquired  through  sexual  spread,  or  parenteral 
contact  with  blood  or  blood  products  in  the  same  way  that  HIV  is, 
hepatitis and HIV infections often coexist. The enteral forms of hepatitis 
(HAV and HEV) are not strongly associated with HIV infection, whereas 
HBV,  HDV,  HCV and HGV are  strongly  associated  because of  shared 
routes  of  transmission.  So  screening  of  these hepatitis  viral  infections 
becomes mandatory in HIV positive patients3.
In case of hepatitis B, C, and D, HIV infection is associated with 
higher  levels  of  replication  of  these hepatitis  viruses,  with  significantly 
greater amounts of virus in serum than among individuals without HIV. 
These higher levels of replication of hepatitis viruses presumably reflect 
deficiencies  in  the  ability  of  the  immune  system  to  control  their 
replication3.
Hepatitis  G  virus  is  a  newly  discovered  virus  which  is  strongly 
associated  in  patients  with  HIV  infection.  This  virus  is  mostly 
asymptomatic, and it has been found in most of the studies that patients 
with HGV RNA had significantly higher CD4 counts, low HIV viral loads 
and slower progression to AIDS, than in patients with HIV alone4.
Screening for these hepatitis viruses has its significance not just 
because  they  are  more  prevalent  and  alters  the  natural  course  of  the 
disease, they do have an important role in treatment. Perhaps the most 
important  consideration  is  the  timing  of  administering  treatment  to 
coinfected patients5.
AIMS AND OBJECTIVES
• To study the serological status of hepatotrophic viral infections 
like  HBV  and  HCV  among  HIV  positive  and  HIV  negative 
patients  attending  Voluntary  Confidential  Counselling  and 
Testing  Centre  (VCCTC),  Government  General  Hospital, 
Chennai.
• To  compare  the  progression  of  Hepatitis  B  virus  infection 
among HIV positive and HIV negative study groups.
• To  compare  the  levels  of  anti  HBs,  among  HIV  positive  and 
HIV  negative  study  groups  with  hepatitis  B  virus  infection, 
during follow up.
• To  detect  the  prevalence  of  HGV  RNA  using  the  RT-PCR 
among HIV positives with coexistent HBsAg and/ or anti HCV.
• To study the clinical stage and immunological status of patients 
with  HIV  infection  at  presentation,  and  their  correlation  with 
hepatotrophic viral infections.
REVIEW OF LITERATURE 
HIV / AIDS
HISTORY AND INTRODUCTION
Human  Immunodeficiency  Virus  (HIV)  which  produces  Acquired 
Immunodeficiency  Syndrome  (AIDS)  was  first  reported  in  the  United 
States in 1981 and has since become a major worldwide epidemic.
AIDS was officially recognized for the first  time in June 1981, at 
the Centre for Disease Control, U.S.A. in previously healthy homosexual 
men  dying  with  Pneumocystis  carinii  pneumonia  and  candidiasis.  In 
1983 the virus causing AIDS was independently identified by a team of 
French scientists led by Dr.Luc Montagnier (Pasteur Institute) who called 
it as Lymphadenopathy Associated Virus (LAV), and American scientists 
team  lead  by  Dr.Robert  C.Gallo  of  Cancer  Institute  and  named  it  as 
HTLV-III7. Jay Levy (Univ of California) isolated this virus from an AIDS 
patient and named it as Human Immunodeficiency Virus.
EPIDEMIOLOGY
India  has had a  sharp  increase in  the  estimated number  of  HIV 
infections,  from  a  few  thousand  in  the  early  1990s  to  around  5.134 
million  children  and  adults  living  with  HIV  /  AIDS  in  20048.  With  a 
population  of  over  one  billion,  the  HIV  epidemics  in  India  will  have  a 
major impact  on the overall  spread of  HIV in  Asia and the Pacific  and 
indeed worldwide.
The  first  case  of  HIV  infection  in  India  was  diagnosed  among 
commercial sex workers in Chennai, Tamil Nadu, in 1986. The greatest 
numbers were in Maharashtra and Gujarat in the west; Tamil Nadu and 
Andhra  Pradesh  in  the  south;  and  Manipur  in  the  north-east9.  The 
majority of the reported AIDS cases have occurred in the sexually active 
and economically productive 15 to  44 age group. Every 24 hours over 
15,000 people are infected with HIV; half of them are between 15 to 24 
years of age10.
The  epidemic  continues  to  shift  towards  women  and  young 
people.  It has been estimated that 38% of adults living with HIV/AIDS in 
India, as of the end of 2003 were women. The increasing HIV prevalence 
among women can consequently be seen in  the increase of  mother to 
child transmission of HIV and paediatric HIV cases.
HIV TYPES AND SUBTYPES
There are two distinct  types of  human AIDS viruses:  HIV-1 and  
HIV-211.  These  two  types  are  distinguished  on  the  basis  of  genome 
organization  and  phylogenetic  (evolutionary)  relationships  with  other 
primate lentiviruses. HIV-2 has only 40% genetic identity with HIV-1, and 
it  is  more  closely  related  to  simian  immunodeficiency  virus.  A  major 
proportion of the infection worldwide is caused by the HIV-1 virus. Based 
on env gene sequences, HIV-1 comprises of three distinct  viral  groups 
(M,N,0); the predominant M groups contains 9 subtypes(A-K, omitting E 
and I). In India and China , subtype C is the most prevalent. Similarly , 
six subtypes of HIV-2 (A-F) have been identified12.
TRANSMISSION
The infection can be transmitted by
1) Blood  and  blood  products  (effective  route  for  viral 
transmission)
• Blood transfusions 
• Intra-venous drug abusers - sharing of needles 
• Health  care  workers:  needle  stick  injuries  -  risk 
approximately 0.36% (depends on extent of the injury) 
2) Organ transplants
3) Sexual intercourse
Both homosexual and heterosexual exposure.
4) Vertical transmission
10 to 40% of babies born to HIV infected mothers will be infected15.
STRUCTURE
HIV is a retrovirus, a member of the Lentivirus genus. It is 120 nm 
in  size,  nucleocapsid  is  icosohedral,  enveloped,  single  stranded  RNA 
virus.  HIV comprises of  an outer  envelope consisting  of  a  lipid  bilayer 
with uniformly arranged 72 spikes or knobs of Glycoprotein (gp)120 and 
(gp) 41. gp 120 protrudes out on the surface of the virus and gp 41 is 
embedded in  the  lipid  matrix.  Just  below the  viral  envelope  is  a  layer 
called  the  matrix,  which  is  made  from  the  protein  p17.  Inside  is  the 
protein core (capsid) which is made from the protein p24. Inside the core 
are  three  enzymes  required  for  HIV  replication  called  reverse 
transcriptase, integrase and protease. Also held within the core is HIV's 
genetic  material,  which  consists  of  two  identical  strands  of  RNA. 
Proteins  p7  and  p9  are  bound  to  the  RNA  and  are  believed  to  be 
involved in regulation of gene expression13.
GENETIC STRUCTURE
HIV  has  several  major  genes  coding  for  structural  proteins  that 
are  found  in  all  retroviruses,  and  several  nonstructural  ("accessory") 
genes that are unique to HIV.
Structural Genes
gag (Group-specific  Antigen):  codes for  p24 ,  the viral  capsid;  p6 
and p7 , the nucleocapsid proteins; and p17 , a matrix protein13.
pol:  Codes  for  viral  enzymes ,  the  most  important  of  which  are 
reverse  transcriptase ,  integrase ,  and  protease which  cleaves  the 
proteins derived from gag and pol into functional proteins.
env (for "envelope"): Codes for the precursor to  gp120 and gp41 , 
proteins  embedded  in  the  viral  envelope  which  enables  the  virus  to 
attach to, and fuse with target cells.
Also in common with the other retroviruses, HIV possess at either 
end  of  its  genome,  a  segment  of  nucleic  acid  called  the  LTR  (long 
terminal repeats). 
Non Structural / Regulatory Genes
tat gene (transactivator of transcription) and rev gene(regulator of 
expression  of  viral  proteins)  are  the  two  most  significant  regulatory 
genes.
In  addition  to  the  gag,  pol,  and  env genes  contained  in  all 
retroviruses, and the  tat and  rev regulatory genes, HIV-1 contains four 
additional genes: nef, vif, vpr and vpu, encoding the so-called accessory 
proteins.  HIV-2  does  not  contain  vpu,  but  instead  harbours  another 
gene,vpx.  The  accessory  proteins  are  not  absolutely  required  for  viral 
replication in all in vitro systems, but represent critical virulence factors 
in vivo14, 15.
IMMUNOPATHOGENESIS
Viral receptors and co-receptors
All primate lentiviruses use as a receptor the CD4 molecule, which 
is expressed on macrophages and T lymphocytes. A second co-receptor 
in  addition  to  CD4  is  necessary  for  HIV-1  to  gain  entry  to  cells.  The 
second  receptor  is  required  for  fusion  of  the  virus  with  the  cell 
membrane.  The  virus  first  binds  to  CD4  and  then  to  the  co-receptor. 
These interactions  cause conformational  change in  the  viral  envelope, 
activating  the  gp41  fusion  peptide  and  triggering  membrane  fusion. 
Chemokine  receptors  serve  as  HIV-1  second  receptors.  CCR5,  the 
receptor for chemokines - RANTES, MIP-1 alpha, and MIP-1 beta, is the 
predominant  co-receptor  for  macrophage  tropic  (M-tropic)  strains  of 
HIV-1.  CXCR4  (fusin),  the  receptor  for  chemokine  SDF-1,  is  the  co-
receptor  for  lymphocyte  tropic  (T-tropic)  strains  of  HIV-1.  Chemokines 
act as potent natural inhibitors of HIV infection, as they bind and down 
modulate chemokine receptors that serve as critical co-receptors for HIV 
to gain access into cells16.
Pathogenesis
After the HIV virus enters its human host, it immediately starts to 
replicate  into  abundance.  The  virus  can  be  located  inside  the  T4 
lymphocytes (helper T cells) and in other classes of  immune cells (like 
macrophages). Early in infection, primary HIV isolates are M-tropic.  As 
the infection progresses, the dominant M-tropic viruses are replaced by 
T-tropic viruses.
Following primary infection, there is a 4 to 11 day period between 
mucosal infection and initial viremia, the viremia is detectable for about 
8  to  12  weeks.  3-6  weeks  after  primary  infection  CD4  counts  drop. 
Immune  response  to  HIV  occurs  1  week  to  3  months  after  infection, 
plasma viremia  drops,  and  levels  of  CD4 cells  rebound.  However,  the 
immune response is unable to clear the infection and HIV persists in the 
lymph nodes. In T cells it can lie dormant indefinitely,  inextricable from 
the  cell  but  hidden  from  the  victim's  immune  system;  when  the  same 
cells  are  stimulated,   however,  it  can  destroy  them  in  a  burst  of 
replication. This period of latency may last for 10 years. During this time, 
there  is  a  high  level  of  ongoing  viral  replication.  The  CD4  count 
decreases steadily,  when it  falls  to  less than 200 clinical  AIDS usually 
sets in13,17.
Replication and Production of New Virions
After HIV enters the bloodstream, it binds its glycoprotein (gp120) 
antireceptor to the CD4 molecule (receptor) on the host cell's membrane 
(HIV co-receptor on lymphocytes is the CXCR4 chemokine receptor) and 
injects  its  core  into  the  host  cell's  cytoplasm21.  The  viral  core  which 
includes two identical strands of RNA, structural proteins, and enzymes. 
Reverse  transcriptase  (the  enzyme  responsible  for  converting  HIV 
genetic material into DNA), first makes a single strand DNA copy of the 
viral  RNA.  Then,  ribonuclease  (an  associated  enzyme)  destroys  the 
original  strands  of  RNA.  The  DNA  polymerase  then  makes  a  second 
copy of DNA using the first  copy as a template.  This process is called 
reverse transcription .The completed viral double stranded DNA is now 
ready to head for the cell's nucleus. Once there, a viral enzyme, called 
an integrase, helps to integrate the viral DNA, or  provirus, into the host 
cell's  DNA.  Viral  transcription  is  now possible  and  every  time  the  cell 
undergoes  replication,  the  provirus  will  be  duplicated  along  with  the 
cell's  own  DNA.  Once  the  virus  reaches  this  stage,  the  infection  is 
permanent. Once the provirus is integrated into the host cell's genome, it 
can remain silent for years or it may become activated to produce new 
virions  .After  the  above  process  is  completed,  the  provirus  exits  the 
nucleus  and  enters  the  cytoplasm  .In  the  cytoplasm viral  proteins  are 
synthesized  and  assembled  with  the  viral.  RNA Maturation  process  is 
completed when the virion components exit the cell through "budding" in 
order  to  gain  its  envelope  and  glycoproteins  which  are  HIV's  final 
structural elements13.
Modes of Cell Death in T cells
There  are  three  main  ways  HIV  incites  cell  death  in  T4  cells, 
namely  through  the  "budding"  process,  cell-to-cell  fusion  (syncytium 
formations), and through tricking the immune system into killing healthy 
T cells13,21.  The consequences of CD4 T cell dysfunction caused by HIV 
infection are devasting, because the CD4 T lymphocyte plays a critical 
role in the human immune response.
COURSE OF HIV INFECTION
Exposure to human immunodeficiency virus (HIV) does not have a 
single  common  outcome  in  all  individuals.  Even  in  the  absence  of 
antiviral  drug  treatment,  several  classes  of  clinical  progression  have 
been defined. 
1. Rapid  progressors,  are  individuals  who  develop  the 
symptoms  of  AIDS,  or  end-stage  HIV  disease,  within  2-3 
years after infection18 About 10% of individuals who become 
HIV-positive fit this profile. 
2. Typical  progressors,  consists  of  individuals  who  develop 
end-stage  disease  within  approximately  10  years  after 
seroconversion. 
3. Long  term  non-progressors  consists  of  those  who  have 
normal CD4+T cell counts after more than a decade of HIV 
seropositivity  without  drug  treatment19.  Approximately  10% 
of  HIV-positive  individuals  appear  to  fit  this  profile.  Such 
individuals also tend to  have low or undetectable levels of 
HIV in their blood20.
THE GENETIC STABILITY OF THE HIV VIRUS
HIV  can  make  thousands  of  duplicates  within  a  single  cell,  so 
genetic  mutations  are  very  common.  Useless  or  inactive  genetic 
mutations  have  little  effect  on  the  virus  as  a  whole,  however,  if 
environmentally  advantageous  mutant  genes  are  produced  and 
continuously selected for  survival,  they are transmitted to other human 
hosts  where  they  undergo  further  genetic  mutations.  These  mutant 
genes  could,  in  time  and  with  enough  human  hosts,  produce  a  new 
serotype of  HIV (HIV-3,  perhaps)21.  Several  mutant  HIV virions can be 
found within a single infected individual, therefore, a vaccine developed 
for one mutant HIV gene may not work against the others13.
WHO DISEASE STAGING SYSTEM FOR HIV INFECTION AND DISEASE 
IN ADULTS AND ADOLESCENTS
The  CD4  lymphocyte  count  is  central  to  the  1993  CDC 
classification system for  HIV disease and to all  of  the staging systems 
proposed  in  developing  countries.  The  Global  Programme on  AIDS  of 
the World Health Organization (WHO) has proposed a simplified staging 
system that is clinically based and flexible enough to be used in different 
parts  of  the  world.  The  system  is  based  on  four  groups  of  clinical 
conditions  that  are  considered  to  have  prognostic  significance  and 
therefore  constitute  stages,  plus  an  assessment  of  physical  activity 
performance  expressed  as  a  four-point  score.  Patients  are  classified 
according  to  the  highest  stage recorded for  either  clinical  condition  or 
physical activity.
CLINICAL CLASSIFICATION
Clinical Stage I:
• Asymptomatic
• Persistent generalized lymphadenopathy
Performance scale 1: asymptomatic, normal activity
Clinical Stage II:
• Weight loss <10% of body weight
• Minor  mucocutaneous  manifestations  (seborrheic  dermatitis, 
prurigo,  fungal  nail  infections,  recurrent  oral  ulcerations, 
angular cheilitis)
• Herpes zoster within the last five years
• Recurrent  upper  respiratory  tract  infections  (i.e.  bacterial 
sinusitis)
And/or performance scale 2: symptomatic, normal activity
Clinical Stage III:
• Weight loss >10% of body weight
• Unexplained chronic diarrhoea, >1 month
• Unexplained prolonged fever (intermittent or constant), >1 
month
• Oral candidiasis (thrush)
• Oral hairy leucoplakia
• Pulmonary tuberculosis
• Severe bacterial infections (i.e. pneumonia, pyomyositis)
And/or  performance  scale  3:  bedridden  <50% of  the  day  during 
last month
Clinical Stage IV:
• HIV wasting  syndrome (weight  loss  of  >10% of  body  weight, 
plus  either  unexplained  chronic  diarrohea  (>1  month)  or 
chronic  weakness  and  unexplained  prolonged  fever  (>1 
month). 
• Pneumocystic carinii pneumonia 
• Toxoplasmosis of the brain
• Cryptosporidiosis with diarrhoea >1 month
• Cryptococcosis, extrapulmonary
• Cytomegalovirus disease of  an organ other  than liver,  spleen 
or lymph node (e.g. retinitis). 
• Herpes simplex virus infection, mucocutaneous (>1 month) or 
visceral
• Progressive multifocal leucoencephalopathy 
• Any disseminated endemic mycosis
• Candidiasis of esophagus, trachea, bronchi
• Atypical mycobacteriosis, disseminated or pulmonary
• Non-typhoid Salmonella septicemia
• Extrapulmonary tuberculosis
• Lymphoma
• Kaposi's sarcoma
• HIV  encephalopathy  (clinical  findings  of  disabling  cognitive 
and/or  motor  dysfunction  interfering  with  activities  of  daily 
living, progressing over weeks to months, in the absence of a 
concurrent illness or condition, other than HIV infection, which 
could explain the findings). 
And/or  performance  scale  4:  bedridden  >50% of  the  day  during 
last month.
THE NEW CDC STAGING SYSTEM
CDC  has  revised  the  classification  system  for  HIV  infection  to 
emphasize  the  clinical  importance of  the  CD4+ T  lymphocyte  count  in 
the categorization of HIV-related clinical conditions
The  previous  CDC  staging  system  divided  the  spectrum  of  HIV 
illness into four (I - IV). This has been replaced with a three-tier system- 
catogories A, B and C23. 
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Criteria for HIV infection for persons ages greater than 13 years: 
a. repeatedly  reactive  screening  tests  for  HIV  antibody  (e.g., 
enzyme immunoassay)  with specific antibody identified by the 
use  of  supplemental  tests  (e.g.,  Western  blot, 
immunofluorescence assay); 
b. direct identification of virus in host tissues by virus isolation
c. HIV antigen detection; or 
d. a positive result  on any other highly specific  licensed test  for 
HIV. 
DIAGNOSIS OF HIV INFECTION
The  methods  for  diagnosis  can  be  broadly  classified  into  direct 
and indirect methods
Direct methods:
1. Virus culture
2. P24 antigen detection
3. Detection of Viral RNA / Pro-viral DNA.
Indirect methods:
 Tests for screening
1. Rapid / simple tests
2. ELISA
 Tests for confirmation
 The Western Blot / Immunoblot
HIV AND HEPATOROPHIC VIRAL INFECTIONS 
In  HIV  infected  individuals,  a  wide  range  of  in  vivo  antigenic 
stimuli seem to serve as cellular activators. Active infection by any virus 
substantially increases HIV viremia. So concomitant viral infections with 
hepatitis viruses may serve as cofactors of AIDS11.
Since the beginning of the AIDS pandemic, hepatic problems have 
been  among  the  most  common  features  of  the  disease.  Despite  the 
introduction of highly active antiretroviral therapy (HAART) in 1995 and 
1996, most HIV-infected patients continue to have liver disorders. 
COMMON HEPATOTROPHIC VIRAL INFECTIONS IN AIDS PATIENTS
 Hepatitis B
 Hepatitis C
 Hepatitis D (coinfection with HBV)
 Hepatitis G
Viral  hepatitis  is  an  important  public  health  problem  worldwide. 
Hepatitis  may  be  caused  by  several  viruses  that  have  in  common 
hepatotropism and tendency to cause liver injury.  They can be broadly 
grouped into  those that  are  blood  borne(Hepatitis  B,C,D,G)  and those 
that are enterically spread(Hepatitis A and E).
Initially,  hepatitis  aquired  by  blood  transfusion,  fresh  frozen 
plasma  infusion  and  administration  of  vaccines  was  called  as  “serum 
hepatitis”  or  “homologous  serum  jaundice”.  Later  it  was  renamed  as 
“Hepatitis  B”  24.  Later  hepatitis  C  virus  was  identified  as  an  agent 
causing  post  transfusion  non-A  non-B  hepatitis25.  Later  it  became 
evident that 15 to 20% of the PT-NANB cases could not be attributed to 
any of the hepatitis viruses that was discovered so far at that time, and 
thus the search for newer hepatitis agent led to the discovery of flavi-like 
virus, called GB virus26 or Hepatitis G virus. It  is readily transmitted by 
blood transfusion, intravenous drug use and may spread sexually. HGV 
has  been  reported  in  adults  and  children  throughout  the  world.  HGV 
infection has been reported in 10 to 20% of adults with chronic HBV or 
HCV  infection,  indicating  coinfection  is  a  common  occurrence.  The 
overall  prevalence  of  HGV infection  among  HIV  positives  was  52.7%, 
with seroprevalence of 32.1% and viremia prevalence of 20.6%27.
Infection  with  hepatitis  viruses  transmitted  through  parenteral 
route  and  sexual  contact  (B,C,G  and  D  )are  more  common  with  HIV 
infection  when  compared to  enteric  hepatitis  viruses  (A,D,E).  Because 
these viruses are transmitted in similar fashions, it is not surprising that 
most HIV seropositive persons are also infected with HBV, HCV or HGV. 
Although  all  these  forms  of  hepatitis  occur  commonly  in  patients  not 
infected with  HIV, they are somewhat more prevalent  and their  natural 
history  may  be  modified  in  patients  with  HIV  infection,  hence  their 
significance. Prevalence rate of these hepatitis viruses with HIV varies in 
different  geographical  situations.  It  depends  mostly  on  the  high  risk 
status of the patient. 
In  addition  to  these  hepatitis  viruses,  there  are  the  universally 
prevalent viruses such as cytomegalovirus, adenovirus, herpes simplex 
virus etc., which can cause hepatitis as part of the clinical presentation, 
though their primary sites of  replication may be in other regions of  the 
body.
HEPATITIS B
Hepatitis B virus was discovered by Blumberg et al in 1967 in the 
blood  of  an  Australian  aborigine  and  thus  its  antigen  is  also  called 
Australia  antigen.  Using  electron  microscopic  methods,  D  S  Dane 
eventually  discovered  virus  like  particles  that  carried  this  antigen  on 
their surface, in the serum of hepatitis B patients28.
 EPIDEMIOLOGY
India has been placed into the intermediate zone of prevalence of 
hepatitis  B  (2-7%  prevalence  rates)  by  the  WHO29.  Nearly  40  million 
people,  out  of  the  global  HBV  infection  pool  of  350  million,  are  from 
India. Approximately 5 to 10% of the patients with HBV infection do not 
clear HBsAg but become HBsAg carriers. As many as 0.2% to 1.0% of 
adults in the United States are chronic HBsAg carriers. The prevalence 
of  the  carrier  state  is  even  higher  in  high  risk  populations  such  as 
homosexuals  (6%)  and  Intravenous  drug  abusers  (7%)30.The  average 
estimated carrier  rate  of  hepatitis  B virus (HBV) in  India  is  4%,  with  a 
total pool of approximately 36 million carriers. Wide variations in social, 
economic, and health factors in different regions may explain variations 
in carrier rates from one part of the country to another31.
TRANSMISSION
The virus is highly infectious and minute amounts of blood / body 
fluids as little as 0.01 microlitre can transmit the infection. Transmission 
of  HBV is  mainly  by the parenteral  route which  involves  direct  contact 
with body fluids. The most common routes are 
• Direct  or  indirect  contact  with  infected  blood  (needle  sticks,cuts 
etc)
• IVDU (sharing needles)
• Unprotected sexual contact
• Transfusion of infected blood and blood products
• Vertical transmission (perinatal transmission).
STRUCTURE
Hepatitis  B virus belongs to  hepadnavirus family with  a  compact 
DNA genome 3.2 kb  in  length.  The virus  particle  (virion)  is  a  complex 
double  shelled  structure  having  an  external  diameter  of  42  nm with  a 
nucleocapsid  core  (27nm)  and  lipoprotein  coat.  This  particle  is  called 
Dane particle. It represents the complete HBV. It replicates in the nuclei 
of infected hepatocytes and posses a distinct antigen called Hepatitis B 
core antigen (HBcAg). The virion core antigen contains DNA polymerase 
and  double  stranded  DNA  molecule.  The  major  structural  protein  is 
lipoprotein viral coat and is called Hepatitis B surface antigen (HBsAg).
TYPES AND SUBTYPES
HBV  has  several  antigenic  subdeterminants,  one  of  which  is 
known as “a”, found in all individuals with HBsAg, and others termed d, 
y,  w and r, which combine with “a” to produce four main HBV subtypes 
(adw, ayw, adr and ayr)30.
PATHOGENESIS
The  incubation  period  of  HBV  infection  is  about  30-180  days, 
during which the patient has no signs and symptoms but the virus may 
be  detected  in  the  blood  stream.  Hepatitis  B  surface  antigen  is 
synthesized  in  the  cytoplasm  of  infected  hepatocytes  in  excess 
quantities  than that  needed for  viral  assembly.  The excess material  in 
the  form  of  small  particles,  either  22nm  spherical  particles  or  small 
tubular  particles  of  varying  lengths  are  released  in  the  blood  stream. 
Since these smaller particles contain only the major viral protein HBsAg 
they  are  considered  non-infectious  but  act  as  markers  of  infection. 
Occasionally complete virus occurs in blood stream. The virion has an 
other marker i.e. Hepatitis B “e” antigen (HBeAg) which is closely related 
to  core  antigen  correlates  with  active  viral  replication,  and  therefore 
associated with high viral load and infectivity32. 
The first detectable viral marker is HBsAg followed by hepatitis B 
e  antigen  (HBeAg)  and  HBV  DNA.  Titers  may  be  high  during  the 
incubation period, but HBV DNA and HBeAg levels begin to fall  at  the 
onset  of  illness  and  may  be  undetectable  at  the  time  of  peak  clinical 
illness.  Core  antigen  does  not  appear  in  blood,  but  antibody  to  this 
antigen (anti-HBc) is detectable with the onset of clinical symptoms. IgM 
- anti HBc is used in an important diagnostic assay for acute hepatitis B 
infection.  Before  current  molecular  assays  were  available,  it  was  the 
only marker detectable at the time between when HBsAg disappears and 
anti-HBs appears, the "window period". Patients who clear the virus lose 
HBsAg and develop anti-HBsAb.  Anti-HBsAb is  a  long-lasting antibody 
and is associated with immunity.  The presence of anti-HBsAb and anti-
HBcAb (IgG)  indicates  recovery  and  immunity  in  a  previously  infected 
individual,  whereas  a  successful  vaccination  response  produces 
antibody only to HBsAg30.
Co-detection  of  HBsAg  and  anti  HBs  was  seen  in  occasional 
patients recovering from acute hepatitis B, and it has been found in upto 
30% of patients with chronic hepatitis33. This co-occurrence may be due 
to simultaneous infection with  different subtypes of HBV34.  This is also 
an indication that immune response to viral envelope is being activated 
in these patients, and this has been proposed as an evidence of greater 
degree of inflammatory activity in such patients and poor prognosis35.
The  risk  of  developing  chronic  infection  (or  the  carrier  state), 
defined  as  the  persistence  of  HBsAg  in  the  blood  for  more  than  6 
months, is dependent on the age and immune function of the patient at 
the  time  of  initial  infection.  Patients  with  chronic  infection  will 
spontaneously clear surface antigen at a rate of 0.5% a year32,36. 
DIAGNOSIS
In the appropriate clinical context, acute hepatitis B is diagnosed 
by detecting HBsAg and IgM core antibody,  or  core antibody alone,  in 
the window period. IgM core antibodies are lost within 6 to 12 months of 
the  onset  of  illness.  Biochemically,  serum  alanine  aminotransferase 
(ALT) and aspartate aminotransferase (AST) levels increase to between 
500  to  5000U/L  and  fall  after  the  acute  phase  of  infection.  Serum 
bilirubin level  seldom increases above 10 mg/dL, alkaline phosphatase 
and  prothrombin  time  are  usually  normal  or  mildly  elevated.  Loss  of 
HBsAg and the development of HBsAb denotes recovery from the acute 
infection and the development of immunity. 
Chronic hepatitis B is defined as the persistence of HBsAg in the 
serum of a patient for at least six months. Patients with chronic infection 
may be divided into  those with  evidence of  active  replication,  typically 
associated  with  abnormal  transaminases  and  higher  viral  loads,  and 
those  in  the  non-replicative  state,  which  is  associated  with  decreased 
markers  of  liver  inflammation  and  damage,  and  lower  viral  loads. 
Transaminases  may  be  normal,  or  increased  anywhere  from  1  to  10 
times the upper limit of normal in chronic infection. The clinical outcome 
of  infection  is  correlated  with  e  Ag  status,  conversion  to  e  antigen 
negative, e Ab-positive in patients with chronic hepatitis B typically leads 
to  decreased  inflammation,  with  normalizing  transaminases  and 
decreased levels of HBV DNA in serum "the inactive carrier" state. 
Chronic HBV infection is associated with a 10-fold increase in the 
risk  of  developing  hepatocellular  carcinoma (HCC).  This  risk  is  further 
magnified  in  the  setting  of  ongoing  inflammation:  in  patients  with  both 
HBsAg  and  HBeAg,  the  risk  increases  to  60-fold  compared  with  the 
general  population.  It  is  therefore  recommended  that  HBV  carriers, 
particularly  those  at  highest  risk  (men  over  age  45,  patients  with 
cirrhosis,  and  those  with  a  family  history  of  liver  cancer)  should  be 
screened with ultrasound and alpha-fetoprotein for HCC, probably every 
6 months36. 
The most  useful  detection methods are ELISA for  HBV antigens 
and antibodies and PCR for viral DNA.
HIV AND HBV CO-INFECTION
Course of hepatitis B with concurrent HIV infection
The  frequency  and  type  of  changes  seen  in  the  course  of  HBV 
infection among HIV-seropositive persons appear to vary with the order 
and age at  which HBV and HIV are acquired.  In HIV-infected patients, 
chronic  hepatitis  B  has  an  unfavorable  course  compared  with 
monoinfected  patients,  and  the  risk  of  liver-associated  mortality  is 
significantly increased.
Upto  95%  of  all  HIV-infected  patients  have  been  infected  with 
hepatitis B,  and  approximately  10-15%  have  chronic  hepatitis B. 
Because  primary  HBV  infection  leads  to  chronic  hepatitis  in  2-5%  of 
immunocompetent  adults,  HIV-infected  patients  experience  chronicity 
about  three to  five  times more  often.  A  possible  reason for  this  is  the 
HIV-associated  T-cell  defect.  A  polarization  to  a  Th2-type  response 
could result in the inhibition of specific cellular defense mechanisms37,38.
Data  from  the  Multicenter  AIDS  Cohort  Study  (MACS)  have 
demonstrated the unfavorable influence of HIV infection on hepatitis B39. 
HIV-positive  patients  possibly  experience  more  frequent  reactivation 
episodes of chronic hepatitis B than HIV-negative patients. Despite the 
worsening described, initially the clinical course is usually more benign 
in  HIV-positive  patients,  although  viral  replication  is  increased.  This 
seems contradictory at first,  but can be explained by the impairment of 
cellular immunity, which may lead to an increase in viral replication, but 
at  the  same  time  also  reduces  hepatocyte  damage.  Therefore, 
transaminases  in  HBV  /  HIV-coinfected  patients  are  frequently  only 
mildly increased.
Influence of HBV on HIV infection
HBV infection neither leads to a more rapid decline of CD4+ cells 
nor  to  an  increased  frequency  of  AIDS-defining  events.  However,  the 
reduction in HIV-associated mortality has led to an increase in mortality 
resulting  from  liver-related  complications.  In  addition,  HAART-related 
hepatotoxicity  develops  about  three  times  more  frequently  in  patients 
with  chronic  hepatitis  B.  Whether  or  not  the  prognosis  of  HBV/HIV-
infected  patients  is  changed  by  HAART  and  HBV  effective  therapies, 
remains to be seen37.
HEPATITIS C VIRUS
HCV was discovered in  1989 and is the most  common cause of 
post transfusion non-A non-B hepatitis.
STRUCTURE
HCV  is  an  enveloped,  single  stranded  RNA  virus,  50-60  nm  in 
diameter  with  a  genome of  10,000 nucleotides25.  HCV is  a  member of 
and shares relationship with Flaviviruses. The genome encodes for three 
structural  proteins;  capsid  protein(C-20KDa)  and  two  envelope 
glycoproteins (EI-gp35 and E2-gp70) and several nonstructural proteins 
(NS)i.e. NS2, NS3, NS4A, NS4B, NS5A, NS5B have been identified.
EPIDEMIOLOGY AND TRANSMISSON
The prevalence of HCV antibodies in blood in developed countries 
ranges  from  0.4-2%.  The  prevalence  of  HCV  in  Indian  blood  donors 
ranges from 0.6 to 2.4%40. 50% of HCV infection is reported to progress 
to  chronic  infection  of  which  20%  may  progress  to  cirrhosis  and 
hepatocellular carcinoma.
Coinfection with  HIV and HCV occurs frequently,  due to  the fact 
that  both  are  transmitted  via  the  same  pathways  (parenteral,  sexual, 
vertical). 240,000 people (30% of HIV-infected individuals) are estimated 
to be infected with both viruses in the USA. As HCV is ten times more 
infectious  than  HIV  on  blood-to-blood  contact,  intravenous  drug  users 
and  recipients  of  blood  products  are  particularly  susceptible  to 
coinfection.
In  contrast,  sexual  transmission of  HCV occurs significantly less 
frequently than HBV or HIV. As a result, HCV is rare in homosexual men 
and coinfection is  more seldom in  this  group.  The risk of  transmission 
probably  depends  on  the  number  of  sexual  partners  and  the 
performance of sexual practices that are prone to injuries. In total, about 
4-8% of all HIV-infected homosexuals are also infected with HCV.
Perinatal  transmission of hepatitis C is rare in immunocompetent 
individuals(<1%).  The  transmission  rate  rises  with  increasing 
immunosuppression in HIV-positive mothers, and is estimated to be as 
high as 20%. On the other hand, HIV-positive mothers treated effectively 
with  HAART do not  appear to have an increased risk for  materno-fetal 
transmission of the hepatitis C virus.
Coinfection of HCV with HBV is associated with a worse outcome.
TYPES AND SUBTYPES
Hepatitis C virus can be grouped into atleast six genotypes .In the 
USA and  Western  Europe,  genotypes  1a  and  1  b  are  most  common, 
followed by types 2 and 3. Genotype 4a is found at high frequency in the 
Middle East, particularly in Egypt. In Africa, infection with the genotypes 
2, 4 and 5 is most predominant, whereas genotypes 1, 3 and 6 prevail in 
South East Asia41. 
CLINICAL COURSE AND PATHOGENESIS
Course in HIV/HCV co-infected patients
The  clinical  course  of  hepatitis  C  and  HIV  coinfection  is 
determined  by  the  HIV-associated  immunosuppression.  Progression  of 
immunosuppression  accelerates  the  course  of  hepatitis  C.  In  the 
American  Multicenter  Hemophilia  Cohort  Study  (MHCS)  it  was  proved 
that rapid progression of liver disease was found particularly in patients 
with CD4+ T-cell counts below 100/m l. In the group of HIV-negative but 
HCV-positive patients, there was not a single case of liver failure during 
the same period of observation. In this group, the latent period until liver 
failure or hepatocellular carcinoma developed is estimated to be 30-40 
years42.
Patients co-infected with HIV and HCV seem to be at significantly 
greater risk of  progression to cirrhosis than patients infected with  HCV 
alone. Fibrosis is more severe, cirrhosis is more common, and mortality 
due to end-stage liver disease is greater in co-infected patients than in 
patients  with  HCV  alone.  HCV  viral  loads  are  generally  higher  with 
concomitant HIV infection, which may account for the more rapid clinical 
progression of HCV in co-infected patients.
Diagnosis
Anti HCV antibodies can be detected in 50 to 70% of the patients 
at the onset of symptoms, whereas in others appearance is delayed 3-6 
weeks.  Antibodies  are  directed  against  core,  envelope,  and  NS3  and 
NS4 proteins and tend to be replatively low in titer. Nucleic acid based 
assays (RT-PCR) detect the presence of circulating HCV RNA and are 
useful  for  monitoring patients on antiviral  therapy.  Nucleic acid assays 
are used to genotype HCV isolates11.
HEPATITIS G VIRUS
Hepatitis G virus is an enveloped RNA virus which belongs to the 
Flaviviridae family.
HISTORY
The  discovery  of  GBV-C  dates  back  to  1967,  when  a  team  of 
German investigators induced self-limiting hepatitis in tamarin monkeys 
that had been inoculated with serum from a surgeon with the initials G.B, 
who  had  developed  acute  hepatitis  in  196443.  In  1995,  a  team  of 
researchers  at  Abbott  Laboratories  isolated  three  viruses from tamarin 
that had been inoculated with the GB agent, which went on to be called 
GBV-A, GBV-B and GBV-C. GBV-A and GBV-B were only detectable in 
nonhuman primates, and that GBV-C was the GB virus responsible for 
hepatitis in humans. 
At  about  the  same time,  researchers  at  Genelabs  Technologies 
made  their  own  discovery  in  chimpanzees  infected  with  sera  from  a 
patient infected with HCV44. A second virus was isolated in this patient, 
which the Genelabs team called the hepatitis G virus (HGV).
It  was determined that the genomic organization of these viruses 
is similar  to  that  of  HCV and all  are considered to be members of  the 
Flaviviridae family.  Comparison of the polyprotein sequences of GBV-C 
and HGV revealed a 95% identity with each other, and has led workers 
to believe that they are closely related, but different isolates of the same 
virus45. For purpose of convenience, these two agents will henceforth be 
collectively referred to as HGV. 
STRUCTURE
HGV is a positive sense, single-stranded RNA virus with sequence 
identity with  various flaviviruses. The genome has approximately 9,400 
nucleotides  and  contains  a  large  open  reading  frame  that  encodes  a 
polyprotein of more than 2,800 amino acids. HGV genome is preceded 
by  5’untranslated  region  (5’UTR),  followed  by  a  long  open  reading 
frame,  terminating  with  the  3’UTR.  The presumed polyprotein  contains 
structural envelope 1 (E1) and 2 (E2) glycoproteins at the amino terminal 
end, followed by non structural  (NS) proteins (NS2, NS3, NS4a, NS4b, 
NS5a, NS5b) at the carboxy terminal end. The HGV polyprotein does not 
appear  to  encode  a  nucleocapsid  protein,  and  the  5’UTR contains  an 
internal ribosome entry site46.Untranslated regions at the 5’ and 3’ ends 
by  (5’UTR  /  5’NCR  and  3’UTR  /  3’NCR  respectively),  flank  the  open 
reading frame of the genome.
HGV  bears  close  similarity  to  GBV-A,  GBV-B  and  HCV  with 
sequence  homologies  of  43.8%,  28.4%  and  26.8%  to  each  of  them 
respectively.  Unlike  HCV however,  in  the  E1  and  E2  regions  of  HGV 
genome, there appear to be no hypervariable regions. Additionally, most 
if not the entire core region, that is seen in the HCV genome, is missing 
for HGV47.
This  virus  encodes  for  genes,  for  a  serine  protease,  a  helicase 
and  an  RNA-dependent  RNA  polymerase,  consistent  with  other  pesti-
and flaviviruses.
EPIDEMIOLOGY AND TRANSMISSION OF HGV
HGV  is  mainly  a  blood  borne  virus  infection  with  world  wide 
distribution.  Its  prevalence  varies  in  different  geographical  locations. 
HGV  is  predominantly  spread  through  parenteral  routes,  principally 
intravenous drug abuse and blood transfusion. HGV prevalence among 
general  population  and blood donors  have  also  found to  be  high.  The 
prevalence of HGV RNA in general population is around 1 to 2% and in 
voluntary blood donors it ranges from 0.5 to 4%48 and in India it is about 
4%49. High rates of HGV of more than 30% were seen in injection drug 
users50. 
HGV  infection  has  been  sought  in  populations  at  high  risk  for 
sexually  transmitted  diseases.  It  is  found  in  higher  rates  among 
homosexuals and commercial  sex workers.  Prevalence of HGV RNA in 
homosexual and bisexual men was found to be 11%51 and in commercial 
sex  workers  20%52.  Maternal-fetal  transmission  rates  was  found  to  be 
more than 30%53.
Few data exist on the prevalence of HGV in HIV infected patients. 
In one study54 HGV RNA was detected in 22.3% of HIV-infected patients.
In another study conducted in Belgium the HGV RNA prevalence 
was found to be 34%55.  Curiously,  two studies of  HIV patients showed 
slower rate of progression of HIV infection in HGV co-infected patients, 
although it is possible that this is due to a confounding variable and not 
the biologic effect of HGV50. 
Studies on HGV infection in acute liver disease showed that HGV 
RNA was detected in  9% of  the patients  with  acute non A-E hepatitis, 
and  coinfections  with  acute  HBV  32%,  HCV  20%.  The  prevalence  of 
HGV in patients with hepatitis B was significantly higher than those with 
hepatitis C or hepatitis non-A-E56. 
Prevalence of HGV RNA in HIV infected HBsAg positive patients 
was 22%,HIV infected anti  HCV positive patients was found to be 16% 
and  HIV  infected  without  markers  for  HBV and  HCV was  found  to  be 
3%70. HGV infection may exacerbate HCV and HBV infection57.
HGV REPLICATION
HGV replicates  like  other  positive  stranded RNA viruses,  with  a 
replicative negative strand intermediary.  In a recent study it  was found 
that  both  genomic  and  antigenomic  strands  of  HGV were  identified  in 
liver,  which implied that HGV replicates in human hepatocytes58.  Some 
studies  concluded  that  it  is  highly  unlikely  that  HGV  replicates  in  or 
infects  hepatocytes  and  the  site  of  HGV  replication  may  be  in 
mononuclear cells in bone marrow or spleen, but not in peripheral blood 
mononuclear  cells  59.  In  another  study  on  HGV,  it  was  found  that  the 
spleen,  bone  marrow,  kidney  and  liver  biopsies  were  found  to  be 
uniformly positive for both negative and positive strands of HGV RNA60. 
PATHOGENESIS
Early  studies  identified  HGV in  patients  with  fulminant  hepatitis, 
suggesting  that  HGV might  play  a  role  in  the  etiology  of  the  disease. 
Recent studies have shown that HGV may be associated with mild acute 
hepatitis but, even though it commonly results in chronic infection, does 
not  seen  to  be  associated  with  significant  chronic  hepatitis  or  liver 
disease61,63.
HGV  clearance  is  common  in  immunocompetent  subjects, 
occurring  in  approximately  60  to  75% of  HGV infected  persons,  along 
with  the  development  of  antibodies  against  the  envelope  glycoprotein 
E262.
Currently,  HGV  is  only  associated  with  a  mild  rise  in 
transaminases  during  acute  infection  not  unusual  for  an  acute  viral 
infection. Persistent infection is probably not associated with significant 
liver  disease,  although some groups disagree.  The high  prevalence of 
HGV infection in the general population makes demonstration of disease 
association particularly difficult.
Although  the  evidence  suggests  that  HGV  is  probably  not 
hepatotropic,  the  virus  is  replicating  somewhere  in  the  infected 
individual.  Many  researchers  have  argued  that  HGV  may  be  a  latent, 
well adapted virus of low virulence.
IMMUNE RESPONSE TO HGV
HGV  RNA  appears  shortly  after  infection  with  HGV,  becoming 
detectable as soon as 2 to 3 weeks after  exposure. In 50% to 75% of 
cases,  the  infected person successfully  clears  HGV infection.  In  these 
cases,  HGV  RNA  disappears  as  anti-E2  becomes  detectable  over  an 
interval  of  several  months.  Seroconversion  to  E2  is  evidence  of  past 
HGV infection and confers immunity against further infection with HGV. 
In  a  minority  of  cases,  HGV  infection  becomes  persistent  for  many 
years50.  Several  studies  have  suggested  that  younger  age  at  time  of 
infection  and  concurrent  or  ongoing  immunosuppression  may  favour 
persistent  infection.  Infection  with  the  hepatitis  G  virus  can  lead  to 
persistent infection in 15 – 30% of adults. Possible mechanisms of HGV 
persistence, as found in some patients, remain to be elucidated65.
Longitudinal  study revealed  that  anti-E2 developed either  during 
viraemia  or  some years  after  seronegativity  for  HGV RNA.  Hence  the 
antibody response itself seemed not to play a major role in the clearance 
of HGV though anti-E2 was associated with the clearance of HGV RNA. 
In contrast to HCV, spontaneous recovery is frequently observed in HGV 
infections64.
Immunity  to  HGV  seems  to  be  long-lasting,  because  circulating 
antibody  to  E2  could  still  be  detected  14  years  after  seroconversion. 
Reactivation  of  HGV after  anti-E2 immune response  has  never  before 
been observed. In some cases of impaired immunocompetence, the loss 
of these antibodies may induce the reactivation of HGV.
CLINICAL FEATURES
Four  different  stages  of  the  clinical  course  of  the  infection  with 
HGV have been noted so far  1. Asymptomatic  2.  Light  Acute hepatitis 
(When the laboratory values and histological  changes are quickly back 
in normal status) 3. Persistent Infection (When the laboratory values and 
histological  changes  persist)  4. Chronic  Infection  (When  histological 
finds are of  that  of  steatosis  with  persistent  or  chronic  active hepatitis 
with fibrosis or Cirrhosis66. Most of the patients show minor elevation in 
aminotransferase levels that last until the clearance of HGV RNA67.
METHODS OF DETECTION FOR HGV
The laboratory diagnosis  of  HGV infection  is  currently  based on 
the  measurement  of  antibodies  against  HGV  envelope  antigen  (E2 
antibodies)  and  on  molecular  biological  assays  to  detect  HGV RNA68. 
However,  anti-E2  antibodies  are  not  detectable  during  HGV  active 
replication ,but they rather seem to be associated with a past infection 
after the clearance of HGV viremia69.  Therefore, the direct detection of 
HGV  RNA  in  biological  specimens  appears  to  be  the  most  reliable 
method for the diagnosis of ongoing HGV infection70.
CURRENT INFECTION
The  reverse  transcriptase  polymerase  chain  reaction(RT-PCR) 
has been the most widely used diagnostic tool for the detection of HGV 
RNA.  RT-PCR  ELISA  was  more  sensitive  than  RT-nested  PCR  for 
detection  of  HGV RNA. HGV was originally identified utilizing degenerate 
oligonucleotide  primers  derived  from  the  putative  NS3  region  of  the 
genome and serum-derived DNA as the template71.  Use of  degenerate 
primers to the NS3 region have also shown high sensitivity in HGV RNA 
detection72.
 The second molecular assay utilized oligonucleotide primer pairs 
from the 5' untranslated region of the virus. Initially primers specific for 
the NS3 region were used73. Later primers derived from the 5'NCR was 
found  to  be  more  efficient  than  those  derived  from  the  NS3 and  NS5 
regions74. 
 Automated  probe-based  assays  have  been  established  for  the 
detection of HGV(Abbott Lcx probe system). 
Hepatitis  G virus infection has also been detected by a modified 
PCR technology which incorporates digoxigenin-labelled nucleotides into 
the amplicon. Primers from the non-coding region and the NS5 region of 
HGV are  utilized  for  a  single  round amplification.  Using  a  streptavidin 
surface and a biotin-labelled capture probe, the labelled nucleic acid is 
bound  through  the  capture  probe  to  the  surface,  and  the  amplified 
nucleic  acid  is  detected  using  antibody to  digoxigenin75.  The amplified 
products  can  also  be  detected  by  a  commercial  assay(GEN-ETI-K-
DEIA,sorin Biomedica).
HGV  quantitation  was  performed  using  a  research-based 
branched  DNA  (bDNA)  assay  with  a  set  of  probes  directed  at  the  5' 
untranslated region76.
A RT PCR using mutant HGV cDNA competitor has been used in 
recent studies59.
PAST INFECTION
An  ELISA  was  used  for  the  qualitative  determination  of  IgG 
antibodies  to  the  HGV  E2  antigen.  Five  purified  prokaryotically 
expressed  recombinant  proteins  were  coated  to  microtitre  plate  and 
used  for  ELISA.  Eight  well-expressed  recombinant  proteins  were 
separated  by  SDS-PAGE  and  transferred  electrophoretically  to 
nitrocellulose for immumoblotting77.
 Anti-HGV(E2)  was  detected  by  using  an  enzyme-linked 
immunosorbent  assay  recently  commercialized  by  Boehringer 
Mannheim-ROCHE  to  the  HGV  E2  antigen  located  putative  on  the 
envelope  of  the  virus  (Anti-Hgenv  Enzymun-test). The  E2 
transmembrane  protein  was  bound  onto  streptavidin-coated  microtiter 
plates,  which  were  incubated  with  the  diluted  specimen,  and  the 
antibodies  directed  against  E2 protein  were  detected  using  an  anti-
human  IgG-peroxidase  conjugate  and  
2,2'  azino  di-[3  etylbenzothiazoline  sulfonate  ]  (ABST)  as  peroxidase 
substrate. Extinction was measured at 405 nm (Anti-HGenv, Boehringer 
Mannheim, Mannheim, Germany)78. 
HGV COINFECTION WITH HIV
Hepatitis G appears to be a harmless hepatitis virus which seems 
to  slow HIV disease progression  dramatically.  The prevalence of  HGV 
RNA in  HIV  patients  was  found  to  be  15%.  Survival  was  significantly 
longer for those who tested positive for HGV79.
In another study, the effects of HGV were found to be independent 
of  age,  HIV-1  load,  HCV  load,  CD4  and  CD8  T  cell  counts,  and  CC 
chemokine receptor 5 (CCR5) genotype80. 
HGV  virus  did  not  prevent  the  entry  of  HIV  in  the  cell  or  the 
depletion of CD4 cells, but it did have an inhibitory effect in replication 
and HIV growth in cell culture. This effect did not appear to be a result of 
cellular  toxicity,  considering  that  HGV  replication  in  peripheral-blood 
mononuclear cells appeared to be noncytopathic and did not inhibit  the 
synthesis of cellular proteins81. 
In addition, some studies suggest that HIV-1 replication is directly 
reduced by HGV. Various stages of the HIV life cycle may be affected by 
HGV, including retroviral  binding and fusion to target  cells through the 
high-affinity receptor and several chemokine coreceptors, internalization 
and reverse transcription, integration into the host-cell genome to create 
the HIV provirus, viral transcription, translation and viral morphogenesis; 
another possibility is a series of interactions that involve CCR5. Hence, 
the internalization of chemokine receptors is an effective mechanism to 
block cellular entry of HIV into the cells [83]. 
The interaction between HIV and HGV is unusual and curious, and 
it  is  beneficial  to  patients  who  are  dually  infected.  It  is,  therefore,  of 
great interest to understand the mechanisms involved in this interaction, 
because  it  could  result  in  progress  in  our  understanding  of  viral 
pathogenesis  and  in  a  contribution  towards  the  development  of  novel 
HIV-1 treatment strategies.
HGV AND HBV
HGV  coinfection  does  not  lead  to  the  activation  of  hepatic 
pathological changes and does not speed up the progression of fibrosis 
in  patients  with  chronic  hepatitis  B  infection.  HGV has at  most  a  mild 
hepatic pathogenicity84.
Reciprocal influence between HBV, HCV and HIV appears rather 
complex,  HBsAg carriage seeming to exert  per se a negative effect  on 
HCV  replication,  particularly  in  HIV-negative  patients,  suggesting  that 
interactions between hepatitis viruses should always be analysed in the 
light of HIV status85.
HGV infection may not affect HBV replication. Liver is the site of 
HGV  replication,  but  HGV  probably  also  replicates  in  extrahepatic 
tissues. HGV hepatic pathogenicity is probably mild and further studies 
are still needed84.
HGV AND HCV
A  high  frequency  of  HGV  coinfection  existed  in  the  hepatitis  C 
patients.  A reverse  relationship was  found to  exist  between HCV RNA 
concentration and HGV infection frequency. 
In  coinfections  of  HGV  with  HCV,  this  virus  did  not  affect  the 
clinical  course  of  HCV.  Peak  serum  ALT  level,  peak  bilirubin  level, 
histologic  severity  of  viremia,  frequency  of  chronic  hepatitis,  and 
response  to  interferon  are  virtually  identical  in  patients  with  combined 
HGV and HCV infection and in those with HCV infection alone. Likewise 
HGV  also  has  no  apparent  influence  on  the  clinical  course  of  acute 
disease among patients with hepatitis A, B or C56.
HGV AND HCV IN HIV INFECTED PATIENTS
Coinfection  with  HCV and  HGV was  present  in  17% of  the  HIV 
infected  individuals  and  8.6%  only  had  HGV  among  HIV  positives. 
Patients  positive  for  HGV-RNA  showed  clinical  and  analytical 
characteristics  similar  to  those  found  in  HGV-RNA  negative  patients. 
Among the HCV- HGV coinfected and those presenting HGV as the only 
virus, it was observed that the coinfected group presented alterations in 
transaminases  and  predominance  of  parenteral  transmission  as  a  risk 
factor for HIV, whereas the HGV group presented normal transaminases 
and  predominance  of  sexual  transmission.  No  differences  were 
perceived  in  mean  CD4  and  HIV-RNA  values  in  both  groups.  Being 
positive  for  HGV  in  HIV-positive  patients  does  not  influence  the 
presence  of  hepatic  disease  that  in  these  patients  is  frequently 
accompanied by coinfection with other hepatotropic viruses. Moreover, it 
does  not  seem  to  influence  the  viremia  of  the  HIV,  or  the  CD4  cell 
counts86.
MATERIALS AND METHODS
DETAILS OF THE STUDY
Setting:
This study was conducted in serologically confirmed HIV positive 
and negative patients attending VCCTC, Government General Hospital, 
Chennai.
Period of study:
March 2004 to February 2006. 
Venue of study:
Study  was  performed  in  the  Institute  of  Microbiology,  Madras 
Medical College, Chennai and The Department of Virology, King Institute 
of Preventive Medicine, Chennai. 
Methodology:
Pre and post test counselling were given to the patients attending 
VCCTC,  and  informed  consent  was  got  from  them  for  testing.  Strict 
confidentiality regarding the results were maintained.
For  ELISA,  blood  samples  were  collected  from  the  patients. 
Serum was separated, and stored at -20°C in cold storage, until use.
For all the ELISAs performed,  the manufacturer’s testing protocol 
instructions were strictly followed and results were interpreted only when 
the validity criteria were satisfied.
HIV SEROLOGY
Antibodies  to  HIV-1  and  HIV-2  were  detected  using  Enzyme 
Linked  Immunosorbent  Assay.  Serum  samples  reactive  for  1st ELISA 
were subjected to 2nd ELISA which utilizes a different principle from the 
first  one.  The sample is considered reactive,  only if  the second ELISA 
confirms the report of the first.
ELISA  for  detecting  antibodies  to  HIV-1  and  HIV-2  in  patients 
serum was performed using Microlisa (  J Mitra& Co Ltd,  India) /  InTec 
( InTec Products, Inc; China).
Microlisa HIV test  is  a  second generation enzyme immunoassay 
based on indirect ELISA. It detects anti HIV antibodies to HIV-1 and /or 
HIV-2  with  equal  reactivity.  The  antigen  used  is  a  complex  of 
recombinant proteins, representing immunodominant epitopes, gp 41, C 
terminus  of  
gp 120 of HIV -1 (including Subgroups O & C) and gp 36 of HIV-2.
InTec  is  an  ELISA  based,  double  antigens  “sandwich” 
immunoassay,  which  employs  a  variety  of  recombinant  HIV  antigens- 
gp120/  gp41/  gp36/  p24 immobilized  at  the  bottom of  microtiter  wells, 
and  recombinant  antigens-  gp120/  gp41/  gp36/  p24  coupled  with 
horseradish peroxidase (HRP) as conjugate solution.
HEPATITIS B SEROLOGY
HBsAg:
ELISA  for  detecting  hepatitis  B  surface  antigen  in  the  patients 
serum  was  performed  using  Hepalisa  (J  Mitra&  Co  Ltd,India)/ 
Microscreen (Span Diagnostics Ltd, India).
Hepalisa  detects  Hepatitis  B  surface  antigen  based  on  direct 
sandwich  principle,  and  Microscreen  is  third  generation  Elisa  for 
screening of HBsAg.
HBeAg:
Hepatitis  B envelope antigen was detected in all  HBsAg positive 
patients using HBeAg EIA (Diazorin, ETI-EBK plus, Ref No:140). It is an 
indirect,  non-competetive  assay  based  on  the  use  of  polystyrene 
microwells  coated  with  mouse  monoclonal  antibodies  to  hepatitis  B 
envelope antigen. An enzyme tracer containing horseradish peroxidase 
labeled  mouse  monoclonal  antibody  to  HBeAg  detects  any  captured 
HBeAg.
Anti HBs:
Antibodies  to  hepatitis  B  surface  antigen  were  detected  in  all 
HBsAg  positive  patients,  during  their  follow  up  after  6  months. 
Qualitative/  Quantitative  determination  of  antibodies  to  hepatitis  B 
surface  antigen  using  anti-HBs  EIA  (Diazorin,  ETI-AB-AUK-3,  Ref 
p001603). It is quantitative\ qualitative, direct, non competitive, sandwich 
assay.
HEPATITIS C SEROLOGY
Anti  HCV  antibody  (anti  HCV)  was  tested  in  the  Anti  HCV  EIA 
(Zhongshan bio-tech Co Ltd, China).  This is a third generation enzyme 
immunoassay for the qualitative determination of antibody to hepatitis C 
virus in human serum/ plasma.
HEPATITIS G VIRUS
RT- PCR FOR DETECTION OF HGV RNA
Collection and processing of clinical samples:
Blood  samples  were  collected  in  nuclease  free  EDTA  coated 
tubes.  Samples  once  collected  were  clearly  labeled  and  stored  in 
refrigerator till centrifugation. After centrifugation, plasma samples were 
stored  at  2  to  8ºC  for  upto  6  hours.  For  long  term  storage  aliquoted 
plasma samples were stored at -60º C, until use.
For  RT-PCR testing,  the recommendations of  Kwok and Higuchi 
were  followed  to  prevent  sample  contamination6.  The  assay  was 
standardized  with  positive  controls  (RNA  extracts/  cDNA  from  known 
positives) got from Department of Virology,  CMC vellore. Subsequently 
all  the  assays  were  performed  with  one  positive  control  and  distilled 
water controls after every third patient’s sample. 
HGV RNA EXTRACTION FROM PLASMA/SERUM
Materials required
- QIA  amp  Min  Elute  Virus  Spin  Kit(Cat  No:57704,  Qiagen, 
Germany).
- Sterile 1.5ml/2ml microcentrifuge tubes.
- 50, 200, 500µl adjustable pipettes and tips.
- Microcentrifuge adjustable to 13K
- Vortexer
- Heating block
HGV RNA was extracted using QIA amp Min Elute Virus Spin Kit, 
according to manufacturers’ instructions, from 200µl of plasma.
Principle and procedure of QIA amp Min Elute Virus Spin Kit
As  the  first  step,  viral  lysis  was  done  with  proteases  and  lysis 
buffer  added to 200µl  sample and incubated at 56ºC for  15 min. Lysis 
buffer  is  Buffer  AL  (containing  28  µg/ml  of  carrier  RNA).  Carrier  RNA 
enhances  binding  of  viral  nucleic  acids  to  the  QIAamp  membrane, 
especially if there are very few target molecules in the sample and also 
reduces the chance of viral RNA degradation. The denaturing conditions 
of the lysis buffer also serves to inactivate RNases.
To  this  alcohol  was  added  to  adjust  buffer  conditions  and  to 
provide ideal binding conditions. The lysate was transferred to the QIA 
amp  Min  Elute  column  containing  silica  based  membrane.  The  viral 
nucleic  acids  were  adsorbed  onto  silica  based  membrane  and  the 
impurities  were  removed,  as  the  lysate  is  drawn  through  by 
centrifugation.  This  was followed  by two  wash steps with  the provided 
wash buffer (AW2 Buffer)  and ethanol which efficiently removed all  the 
inhibitors  of  the  RT  PCR  reaction.  The  columns  were  spin  dry  and 
incubated  at  56ºC  for  3  min  to  dry  membrane  completely  as  ethanol 
carryover  may  cause  problems  in  downstream  applications.  The  RNA 
was eluted finally in 100 µl of elution buffer provided with the kit.
The extracted RNA was used immediately for c DNA synthesis.
REVERSE TRANSCRIPTION
Materials required
- QIA  amp  one  step  RT  PCR  Kit  (Cat  No:210210,  Qiagen, 
Germany)
- Sterile 0.5 ml microcentrifuge tube
- 10, 20, 100 µl adjustable pipettes and tips
- vortexer
- Gene Amp PCR System 2400 thermal cycler ( Perkin –Elmer, 
USA)
- Viral RNA
- Forward and Reverse primers specific  for  5’NCR region of 
the  HGV  genome  (Cat  No:  Primers_  (2  OD),  Qiagen, 
Germany).
PCR PRIMERS USED FOR AMPLIFICATION 
AND DETECTION OF HGV RNA
 HGV Primer  No of bases  Nucleotide sequence (5’ – 3’)
5’NCR forward
primer
20 CGG CCA AAA GGT GGT GGA TG
5’NCR reverse
primer
19 CGA CGA GCC TGA CGT CGG G
Procedure
All the reactions were carried out on ice.
Preparation of Master Mix
Master Mix was prepared with its final concentration containing 1x 
RT  Buffer  having  12.5  mM  MgCl  2,  400  µM  of  each  dNTPs  ,  1x 
concentration of Q solution, 0.6 µM of Primer A, 0.6 µM of Primer B and 
2µl of Qiagen one step RT PCR enzyme mix per reaction.
To  40µl  of  Master  Mix,  10µl  of  template  RNA  (extracted  from 
patients  plasma)  was  added  to  make  it  to  a  total  volume  of  50µl  per 
reaction.
Known  positive  and  negative  controls  were  included  in  every 
reaction.  The  negative  control  lacks  template  RNA,  in  order  to  detect 
possible contamination of the reaction components.
HGV PCR
Thermal cycling conditions included initial temperature of 50°C for 
30  min  for  reverse  transcription,  followed  by  45  cycles  of  94°C  for  1 
minute and 30 seconds, 55°C for 1 minute and 30 seconds, and 72°C for 
1 minute and 30 seconds followed by a final extension step at 72°C for 
10 minutes in the thermal cycler.
Pre and post  PCR reactions were carried out in different rooms. 
Aerosol  barrier  tips  were  used  at  all  micropipetting  steps.  Change  of 
disposable plastic gloves after handling of each sample was followed.
Detection of amplified products by Gel detection method
The  amplification  product  was  analysed  in  2% agarose  gel  with 
0.5µl  of  ethidium  bromide  and  viewed  under  UV  illumination  (Alpha 
Innotech,  USA).  Phi  174x  Hae  digest  (Boehringer  Mannheim-  Roche, 
Gmbh, Germany)  was used as the molecular weight standard for  each 
assay.
The specific amplified product from the 5’NCR region of the HGV 
genome was 186 bp in size.
Determination of CD4\CD8 counts 
CD4  and  CD8  counts  were  determined  with  the  help  of  FACS 
count system (Becton Dickinson Immunocytometry systems).
Control runs were set up each time when the instrument is run, or 
when a new lot of reagents were used.
About 3 ml of  blood samples were collected in K3 EDTA (liquid) 
VACUTAINER tubes and tested on the same day of collection.
ELISA - HIV
ETHIDIUM BROMIDE STAINED AGAROSE GEL 
PRODUCTS AFTER RT-PCR FOR THE 5’ NCR 
REGION OF HGV GENOME
Lane 1 - Hae III digest of φX174
Lane 2 - Positive Control
Lane 3 - Negative Control
Lane 4,6,10 - Positive Samples
Lane 5,7,8,9 - Negative Samples
ELISA - HBsAg
RESULTS
TABLE Ι  - AGE AND SEX DISTRIBUTION
Age in years HIV positives(n = 500)
Male Female
Total
HIV negatives
(n = 300)
Male Female
Total
 15 - 20  3  1  4 (0.8%)  1  0  1
(0.3%)
 20 - 29  72  69  141
(28.2%)
 25  12  41
 (13.7%)
 30 - 39  175  85  260
 (52%)
 130  60  190
(63.3%)
 40 - 49  68  11  79
(15.8%)
 45  12  57
 (19%)
 > 50  15  1  16
 (3.2%)
 10  1  11
 (3.7%)
 
 Total
 
 333
 
 167  500
 
 211
 
 89  300
      %  66.6  33.4  70.3  29.7
• Maximum number of HIV positives were between 30 to 39 years 
(median age-34 years)
• The male: female ratio was 1.9: 1
TABLE II  
PREVALENCE OF HBSAG AND ANTI HCV 
AMONG HIV POSITIVES AND NEGATIVES 
HIV Status HBsAg Percentage Anti HCV Percentage
 HIV positives
 ( n = 500)
24
4.8 20 4
 HIV negatives
 ( n = 300)
26 8.6 10 3.3
Prevalence  of  Hepatitis  B  surface  antigen  was  more  both 
among  HIV  positives  and  negatives,  when  compared  to  anti  HCV 
antibodies.
TABLE III 
 MARKERS OF HBV
HIV status
HBsAg 
positives 
in 1st  
screening
%
HBsAg 
positives
in 2nd screening 
(after 6 months)
% HBe Ag
HIV positives
(n = 500)
24 4.8 5 20.8 4
HIV negatives
(n = 300)
26 8.6 2 7.6 2
• The  persistence  of  Hepatitis  B  surface  antigen  after  6  months  was 
three  times  more  among  the  HIV  positives,  when  compared  to  the 
HIV negative study group.
• The presence of  HBeAg which  indicates active replication was also 
more among HIV positives when compared to negative study group.
TABLE IV
ANTI HBS LEVELS AMONG HBSAG POSITIVES 
AFTER 6 MONTHS FOLLOW UP
Study Group HBsAg
Anti HBs levels
1- 10 IU/L >  10 IU/L
HIV positives
(n = 500)
24 7
(29.1%)
1
(4.1%)
HIV negatives
(n = 300)
26 13
(50%)
4
(15.4%)
• HIV  negative  patients  had  higher  antibody  levels,  when 
compared to HIV positive study group.
• Among the  5  patients  who  had  chronic  HBV infection  (Table 
III),  2 had coexistent anti-HBs in their serum.
TABLE V 
PROBABLE ROUTES OF TRANSMISSION OF HIV
Transmission Route HIV positives (n = 500) %
 Heterosexual 420 84
 Homosexual 6 1.2
 Bisexual 9 1.8
 IVDUs 16 3.2
 Unknown 49 9.8
• Heterosexual route was the major mode of transmission of HIV .
• The heterosexuals also included the spouse of infected men.
TABLE VI 
PROBABLE ROUTES OF TRANSMISSION OF HBV AND HCV
Routes of 
transmission
HBsAg 
Positives
( n = 24)
%
Anti HCV 
positives
(n =20)
%
Heterosexual 16 66.7 3 15
Homosexual 2 8.3 1 5
 IVDUs 3 12.5 14 70
 Unknown 3 12.5 2 10
• Heterosexual route was the major mode of transmission of HBV.
• HCV was more prevalent among IVDUs 
• Among the total 16 IVDUs (Table II), 2 (12.5% ) were positive for 
both HBsAg and Anti HCV
TABLE VII 
WHO STAGING FOR HIV POSITIVES WITH AND WITHOUT 
HEPATOTROPHIC VIRUS INFECTIONS
Study population
Clinical 
Stage I
Clinical  
Stage II
Clinical  
Stage III
Clinical  
Stage IV
A B C A B C A B C A B C
HIV positives
with
hepatotrophic 
virus infection
( n = 42)
HIV+ HBV+
(n=24)
1 2 0 1 6 10 0 1 3 0 0 0
HIV+  CV+
(n =20)
1 4 2 0 4 7 0 1 1 0 0 0
Total (n = 42) 2 6 2 1 10 15 0 2 4 0 0 0
HIV positives without
hepatotrophic virus
infection ( n = 458)
60 79 3 29 105 42 2 28 60 0 3 47
Total HIV positives
( n = 500)
62 85 5 30 115 57 2 30 64 0 3 47
 Category A: CD4 counts > 500
 Category B: CD4 counts 200- 500
 Category C: CD4 counts <200
• Majority  of  the  HIV  positives  without  hepatotrophic  viral 
infections were in Clinical Stage II Category B of HIV infection.
• Majority  of  the  patients  who  were  positive  for  hepatitis  viral 
markers were in Clinical Stage II Category C of HIV infection
 TABLE VIII 
COMPARISON OF CD4 COUNTS AMONG HIV POSITIVES WITH AND 
WITHOUT HEPATITIS MARKERS
Study Group CD4 + / mm
3
A>  500 B200-500
C
<  200 Mean+ SD
HIV with hepatitis markers 
(HBsAg & anti HCV) 
( n = 42)
3
(7.1%)
16
(38.1%
)
23
(54.3%
)
210.11+ 120.9
HIV without hepatitis markers
(HBsAg  &  anti  HCV)  
( n = 458)
91
 (19.9%
)
 217
(47.3%
)
150
(32.8%
)
316.43+ 177.9
HIV  positives  with  hepatotrophic  virus  infections  had  less  mean 
CD4 counts, when compared to HIV positives without hepatotrophic virus 
infections.
TABLE IX 
ALT LEVELS AMONG HIV POSITIVES WITH 
COEXISTENT HEPATITIS VIRUS INFECTIONS
Study 
Group
Hepatitis Virus 
Markers
ALT Values
Normal <  3 times 
ULN*
>  3 
times 
ULN*
Mean 
+ SD
HIV 
Positive
s
(n= 500)
HBsAg positive
s (n=24) 18 (75%) 2 (8.3%)
4(16.7%
) 49.5+ 43.2
Anti HCV 
positives(n=20) 6 (30%) 7(35%) 7(35%) 71.5+ 42.5
HIV 
negative
s
(n=300)
HBsAg 
positives
( n= 26)
14(53.8%
)
10(38.5%
) 2(7.7%) 37.5+ 25.5
Anti  HCV 
positives
 (n = 10)
3(30%) 5 (50%) 2 (20%) 53.8+ 35.3
*ULN- Upper Limit of Normal
Mean  serum  ALT  levels  were  more  among  the  HIV  positive 
patients  who  were  co-infected  with  HBV  and  /  or  HCV  when 
compared to HIV negative study group.
TABLE X 
PREVALENCE OF HGV RNA AMONG HIV POSITIVES
Study group
Hepatitis virus
marker status
HGV RNA %
 HIV Positives
 (n = 500)
HBsAg positives
 (n = 24)
6  25
Anti HCV positives
 (n = 20)
7  35
The  prevalence  of  HGV  RNA  was  more  in  anti  HCV  positive 
patients  when  compared  to  HBsAg  positive  patients,  among  the  HIV 
positive study group.
TABLE XI
PROBABLE ROUTES OF TRANSMISSION OF HGV AMONG HBV AND HCV 
POSITIVE INDIVIDUALS WITH HIV INFECTION
Routes of transmission
HGV positives ( n = 13 )
HIV+ HBV+
(n = 6)
HIV+ HCV+
(n = 7)
 Heterosexual 3 (50%) 1 (14.3%)
 Homosexual 1 (16.7%) 0
 IVDUs 0 6 (85.7%)
 Unknown 2 (33.3%) 0
Sexual route was the predominant mode of transmission of HGV 
among HBV positives with HIV, whereas parenteral route was the major 
mode of transmission of HGV among HCV positives with HIV infection.
TABLE XII 
   COMPARISON OF CD4 COUNTS BETWEEN HGV RNA POSITIVE AND 
NEGATIVE INDIVIDUALS
Study 
group
HGV 
Status
CD4 +/ mm3
>  500 200- 500 <  200
Mean + SD
HIV+/ 
HBV+
(n= 24)
 HGV +
 (n= 6)
2(33.33%
)
2(33.33%
)
2(33.33%
)
308.3+ 204.3
 HGV –
 (n=18)
0 7(38.9%) 11(61.1%
)
181+ 78.5
HIV+/ 
HCV+
(n= 20)
 HGV +
 (n=7)
0 5 (71.4%) 2(28.6%) 198.1+ 55.5
 HGV –
 (n=13)
1(7.7%) 4(30.8%) 8(61.5%) 212.4+ 135.3
• HGV  positive  individuals  had  higher  mean  CD4 counts  when 
compared to HGV negative individuals,  among the HIV positive and 
HBsAg positive study group.
• There  was  no  significant  difference  observed  between  the  HGV 
positive and negative patients, among the HIV positive &  anti  HCV 
positive study group.
TABLE XIII
COMPARISON OF ALT LEVELS BETWEEN 
HGV RNA POSITIVES AND NEGATIVE INDIVIDUALS
Study 
Group
HGV 
status
ALT Values
Normal <  3 times ULN*
>  3 times 
ULN*
Mean+ SD
HIV+ / 
HBV+
(n= 24)
 HGV +
 (n=6)
1
(16.7%)
3
(50%)
2
(33.3%)
65.7+ 42.3
 HGV -
 (n=18)
13
(72.2%)
3
(16.7%)
2 
(11.1%)
44.0+ 43.2
HIV+/ 
HCV+
(n=20)
 HGV +
 (n=7)
1 
(14.3%)
3
(42.9%)
3
(42.9%)
79.0+ 36.6
 HGV -
 (n=13)
5
(38.5%)
4
(30.8%)
4
(30.8%)
67.5+ 50.6
Mean  serum  ALT  levels  were  more  among  HGV  positive 
individuals, when compared to HGV negative individuals.
DISCUSSION
Hepatotrophic  virus  infections occur  more  commonly among HIV 
positive individuals. Their prevalence depends on the geographical area 
& high risk behaviour; and their immunopathogenesis differs among HIV 
infected  and  non  infected  individuals.  Institution  of  Highly  Active  Anti 
Retroviral  Therapy  (HAART)  also  requires  a  knowledge  about  these 
viruses.  The  present  study  is  focused  on  the  prevalence  of  the 
hepatotrophic  viruses  and  their  clinical  course  which  would  help  the 
physician in appropriate management and treatment.
In the present study, patients between 30 to 39 years of age were 
predominantly affected with HIV. The average age is 34.5 years (Table 
I).  This  correlated  well  with  the  previous  datas  available,  where  the 
predominant  age  group  was  given  under  a  broader  range  of  30-49 
years9.  HIV  mainly  affects  people  in  sexually  active  age  group,  which 
indirectly implies sexual route may be the major mode of transmission of 
HIV.
There  was  a  male  predominance,  with  male:  female  ratio  being 
1.9:1 in our study (Table I).  In the previous studies conducted in 1998 
the male: female ratio was about 3:187. Latest study by Cacala SR et al 
in  2006 has shown male:  female ratio  of  1.4:188,  which  correlates  well 
with  the present study.  The increase in the number of females may be 
due to  the  effective  awareness created  among them,  which  has made 
them  come  to  voluntary  confidential  counseling  and  testing  center  for 
HIV testing.
The prevalence of HBsAg was 4.8% and anti HCV was about 4%, 
among the HIV positives in our study.  Among the HIV negatives, 8.6% 
were  HBsAg positive and 3.3% were anti  HCV positive (Table II).  In a 
study conducted by S M Ahsan et al  in Mumbai during 2002 showed a 
seroprevalence of about 3.5% for HBsAg and 8% for anti  HCV, among 
HIV  positives89.  In  a  study  conducted  by  chandrasekaran  S  et  al  in 
Madurai  showed a prevalence rate  of  18.2% for  HBsAg and 3.4 % for 
anti  HCV, among suspected hepatitis cases who were HIV negatives90. 
The differences in the prevalence observed are due to the variations in 
the  prevalence  rates  among  different  geographical  situations,  and 
depends mostly on the high risk status of the patient.
In our study, among the 24 HIV positives who had HBsAg in their 
serum  during  the  initial  screening,  when  they  were  screened  after  6 
months follow up, 5 (20.8%) had persistent HBsAg in their serum which 
indicated  their  chronicity.  In  HIV  negative  study  group,  among  the  26 
who had HBsAg in their serum during the initial screening, only 2 (7.6%) 
had  persistent  HBsAg  in  their  serum  and  had  chronic  hepatitis  B 
infection (Table III).  Chronicity was about 3 times more among the HIV 
positives  when  compared  to  the  HIV  negatives  in  our  study.  Mandells 
principles  and  practice  of  infectious  diseases  textbook  states  that 
approximately 5 to 10% of the patients with HBV infection do not clear 
HBsAg,  but  become  chronic  HBsAg  carriers;  and  among  the  HIV 
positives  infected  with  HBsAg  about  10-15%  have  chronic  hepatitis B 
infection30.  HIV  infected  patients  experience  chronicity  about  three  to 
five times more often than HIV negatives,  and this correlates well  with 
our study.
Around  4  (16.6%)  of  the  HIV  positives  and  2(7.6%)  of  the  HIV 
negatives who had HBsAg in their  serum during  initial  screening,  had 
HBeAg in their serum, and were in active replicative state (Table III). HIV 
positives with hepatitis B infection were more infectious and had a poor 
clinical outcome when compared to HIV negatives in our study, and this 
correlates well with the previous studies30.
In  the  present  study,  anti  HBs  levels  were  accessed  after  6 
months among the patients  who were  HBsAg positive during the initial 
screening.  This  was  done  to  access  the  clearance  of  HBsAg  and 
development of protective anti HBs levels. Among the 24 HIV positives, 
who were HBsAg positive initially (before 6 months), only one had anti 
HBs level in protective levels (more than 10 IU/L), and in 7 anti HBs was 
just detected but below the protective levels. Among the 26 HIV negative 
& HBsAg positive study group, after 6 months four had anti HBs levels in 
protective  levels  (  more  than  10  IU/L),  and  in  13  anti  HBs  was  just 
detected but below the protective levels (Table IV).
 Among the 5 HIV positive patients  who had chronic  hepatitis  B 
infection, 2 had coexistent anti  HBs in their serum, in our study (Table 
IV). As per shiels et al(1987) co-occurrence of HBsAg and anti HBs has 
been observed in occasional patients recovering from acute hepatitis B, 
and  it  has  been  found  in  upto  30%  of  patients  with  chronic  hepatitis 
which correlates well with our study33. This co–occurrence is associated 
with a greater degree of inflammatory activity and poor prognosis.
Heterosexual  route  was  the  major  mode  of  transmission  of  HIV 
which accounted for about 84% of the total, in the remaining about 3.2% 
were IVDUs, 1.2% were homosexuals, 1.8% were bisexuals and in about 
9.8%  the  mode  of  transmission  was  not  known  (Table  V).  The 
heterosexual population also included the spouse of infected men. Most 
of  the males gave history of  contact  with  multiple partners and unsafe 
sex. A recent study conducted by NACO in 2005 showed that about 85% 
of  the  transmission  of  HIV  was  through  sexual  route  and  about  2.4% 
were IVDUs9, which correlates well with the present study. Heterosexual 
route is the major route of transmission of HIV in India .
The  major  mode  of  transmission  of  hepatitis  B  virus  was 
heterosexual route which was about 66.7%. Among the rest, about 8.3% 
were  homosexuals,  12.5%  were  IVDUs  and  in  12.5%  the  mode  of 
transmission was not known. Among the HIV positive homosexuals who 
were seropositive for HBsAg2, one developed carrier state (Table VI). As 
per  Mandells  principles  and  practice  of  infectious  diseases,  risk  for 
transmission  of  HBV in  heterosexuals  is  about  41%,  homosexuals  9% 
and  IVDUs  15%30.  Transmission  of  HBV  by  heterosexual  route  was 
more  in  the  present  study,  since  the  transmisson of  the  hepatotrophic 
viruses depends on the geographical area.
 Majority  of  the  HIV  positives  with  anti  HCV  antibodies  were 
IVDUs (70%).  Among  the  remaining,  about  15% were  heterosexuals  , 
5% were homosexuals and in about 10% the route of transmission was 
not  known(Table  VI).  As  per  Miriam  J.  Alter  et  al(2006),  72-95%  of 
injection drug users, 1-12% of homosexuals and 9-27% of heterosexuals 
had  HCV  infection,  among  the  HIV  infected  patients91,   and  this 
correlates well with the present study.  
In  the  present  study,  majority  of  the  HIV  positives  without 
hepatotrophic virus infections (22.9%) were in Clinical Stage II Category 
B of  infection.  Most  of  the  patients  (35.7%) who  were  seropositive  for 
hepatitis  viral  markers  were  in  Clinical  Stage  II  Category  C  of  HIV 
infection (Table VII). In a study conducted by SV Jalgoankar et al, 2003, 
there was a significant difference between the symptomatic- CDC stage 
IV(71.4%)  and  asymptomatic-  CDC  stage  II  (28.6%)  of  HIV  infected 
patients  who  had coexistent  HBsAg or  anti  HCV in  their  serum92.  This 
study  correlates  well  with  the  present  study  which  also  showed  the 
difference.  The  incidence  of  co-infection  rises  with  the  disease 
progression, hence the difference.
          Majority of the HIV positives with hepatotrophic virus infections 
(HBV and or HCV), had CD4 counts below 200 (54.8%) in our study.  All 
the  patients  with  chronic  hepatitis  B  infection  were  in  this  category. 
Whereas in  HIV positives  with  no  detectable  hepatitis  viral  markers  in 
the  serum,  only  32.8%  had  CD4  counts  below  200  (Table  VIII).  In 
previous studies among HIV positive patients with HBV/ HCV coinfection 
have  shown  that  they  are  associated  with  lower  CD4  counts3 which 
correlates  well  with  the  present  study.  This  carriers  its  significance 
because  in  a  previous  study (American Multicenter  Hemophilia  Cohort 
Study)  it  was proved that rapid progression of  liver  disease was found 
particularly in patients with CD4+ counts below 100/m l. 
 In  the present  study,  among the HIV positives,  four  hepatitis  B 
carriers had ALT levels more than 3 times the upper limit of normal and 
were active carriers of hepatitis B infection. One patient (HIV and HBsAg 
positive) who was a carrier, neither had HBeAg nor elevated ALT levels 
and was a healthy carrier of HBV infection. Among the HIV negative and 
HBsAg positive study group 2 (7.7%) had ALT levels more than 3 times 
the upper  limit  of  normal  ,  whereas 4 (16.7)% of  the HIV positive and 
HBsAg positive study group had ALT levels more than 3 times the upper 
limit of normal. This  implies that the rise in ALT levels is more among 
HIV positives when compared to HIV negatives (Table IX). In a previous 
study by Gregory J Dore et al,  in National Centre in HIV Epidemiology 
and Clinical Research, Australia, among the 23 HIV positives who were 
positive for HBsAg , 8 had abnormal ALT levels (more than upper limit of 
normal)93 which was about 6 in the present study.
Among  the  HIV  positives  who  had  coexistent  anti  HCV,  7(35%) 
had ALT levels more than 3 times the upper limit of normal. Among the 
HIV negatives who had coexistent anti HCV 2(20%) had ALT levels more 
3  times  than  upper  limit  of  normal  (Table  IX).  In  a  previous  study  by 
Margaret  J  Koziel  et  al  (2002),  among  the  HIV  positives  with  HCV 
coinfection, 31% had normal ALT levels, 42% had ALT levels less than 2 
times ULN & ALT levels were more than 2 and 3 times the ULN in 15% 
and 12%, respectively94. This correlates well with the present study. As 
per Conry-Cantilena C et al (1996), around 30% of patients with chronic 
HCV infection had elevated ALT levels, 40% had ALT levels close to the 
upper limit of normal (<2 times the upper limit of normal) and 30% had 
normal ALT95, which correlates well with the present study.
In  the  present  study,  prevalence  of  HGV  RNA  in  HIV  infected 
HBsAg  positive  patients  was  about  25  %,  and  HIV  infected  anti  HCV 
positive  patients  was  found to  be  35%.  Two patients  who  had chronic 
hepatitis B infection had coexistent HGV RNA (Table X). Prevalence of 
HGV  RNA  among  HIV  infected,  anti  HCV  positives  was  more  when 
compared to HIV infected HBsAg positives in our study. As per Bonacini 
M et al(1998),  prevalence of HGV RNA in HIV infected HBsAg positive 
patients was 22 %, HIV infected anti HCV positive patients was found to 
be 16%54.  The prevalence rate varies in our study, since it depends on 
the geographical area and high risk status of the patient.
In  the present  study,  among the HGV positives  majority of  them 
were  IVDUs(46%),  about  31%  were  heterosexuals,  15.38%  were 
homosexuals and in about 8% the route of transmission was not known. 
Sexual transmission was the predominant mode of transmission of HGV 
among HBV positives with HIV (50%), whereas parenteral route was the 
major  mode  of  transmission  of  HGV  among  HCV  positives  with  HIV 
(85.7%)(Table XI).  As per Kleinman et al  (2001),  high rates of  HGV of 
more than  30% were  seen  in  injection  drug users50,   which  correlates 
well  with  the present  study.  As per  Stark  K et  al(1996),  prevalence of 
HGV  RNA  in  homosexual  and  bisexual  men  was  found  to  be  11%51, 
which correlates well with our study. 
In the present study, around 2 (33.33%) of the HIV positives who 
had  coexistent  HBV  and  HGV  infections  had  CD4  counts  below  200, 
whereas  about11 61.1% of  the  HIV  positive,  HBsAg  positive  and  HGV 
negative  study  group  had  CD4  counts  below  200.  Among  the  HIV 
positive, HCV positive and HGV positive study group, only 2 (28.6%) had 
CD4 counts below 200, whereas about 8 (61.5%) had CD4 counts below 
200 among the HIV positive,  HCV positive,  HGV negative  study group 
(Table  XII).   Majority  of  the  patients  who  were  positive  for  HGV RNA 
along with  HBV, had higher CD4 counts when compared to  HGV RNA 
negatives with HBV among HIV positive patients. As per  T.Tsertsvadze 
et al( 2001), CD4 count was higher in patients with  HIV, HBV and HGV 
combined infections in comparison with  HIV positive,  HBV positive and 
HGV negative patients96, which correlates well with the present study.
       About 2 (33.3%) out of total 6 HIV positive, HBV positive and HGV 
positive individuals had ALT levels more than 3 times the upper limit of 
normal,  whereas  among  the  HIV  positive,  HBV  positive   and  HGV 
negative  study  group  about  2(11.1%)  of  the  total  18  had  raised  ALT 
levels more than 3 times the upper limit  of  normal  (Table XIII).  As per 
T.Tsertsvadze et  al  (  2001),  Significantly  higher  ALT  levels  were 
observed in the subgroup of patients with HIV, HBV and HGV combined 
infections  in  comparison  with  HIV  positive,  HBV  positive  and  HGV 
negative  individuals96,   which  correlates  well  with  the  study.  In  the 
present  study ,  3 (42.9%) of  the HIV positive,  HCV positive and  HGV 
positive   study  group  had raised ALT levels  (more  than  3  times  ULN) 
when compared to 4(30.8%) of the HIV positive, HCV positive and HGV 
negative  study group.  A previous study by  Lopez Calvo et  al  (2003)97 
also confirmed the same. 
SUMMARY AND CONCLUSION
• In  the  present  study  500  HIV  positive  and  300  HIV  negative 
patients  attending  VCCTC,  Government  General  Hospital, 
Chennai  were  screened  for  the  coexistence  of  hepatotrophic 
virus  infections.  Majority  of  the  HIV  positives  were  in  the 
sexually active age group of 30 – 39 years ( 52%), with males 
being more than females in the ratio of 1.9: 1.
• Heterosexual route was the major mode of transmission of HIV 
( 84%).
• Hepatitis  B  surface  antigen  was  the  more  prevalent  viral 
marker among HIV positives (4.8%) and HIV negatives (8.6%), 
when compared to anti HCV antibodies.
• Transmission of  HBV was  mainly through sexual  route (75%) 
and  transmission  of  HCV  was  mainly  through  parenteral 
route(70%), among the HIV positives.
•  Among the 5 HIV positives who had chronic HBV infection, 4 
were  ‘chronic  active  carriers’  with  CD4  counts  below  200  & 
ALT  levels  more  than  3  times  ULN  and  one  was  a  ‘Healthy 
carrier’ who neither had HBeAg, nor raised ALT levels..
• The chronicity of HBV was about 3 times more common among 
the  HIV  positives(20.8%),  when  compared  to  the  HIV 
negatives(7.6%),  which  implies  that  HIV  positives  with  HBV 
infection were more infectious and had a poor prognosis when 
compared to HIV negative study group.
• HIV  negative  study  group  had  higher  mean  anti-HBs  levels, 
when compared to HIV positive study group, during their follow 
up after 6 months. This implies that HIV associated depressed 
cellular  defence mechanism may be the cause for  diminished 
anti-HBs  levels.  Among the  5  HIV positives  who  had  chronic 
hepatitis B infection, 2 had co-existent anti HBs in their serum.
• Majority  of  the  HIV  positives  with  hepatitis  B  or  C  infections 
had lower mean CD4 counts, when compared to HIV positives 
without  hepatotrophic  virus  infections.  This  shows  that 
hepatotrophic viruses affect the course of HIV infection.
• Among  the  HBsAg  and  anti  HCV  positives,  ALT  levels  were 
raised  more  among  the  HIV  positive  study  group  when 
compared  to  HIV  negatives  signifying  that  the  course  of 
hepatitis B and C is accelerated in HIV coinfection.
• HGV  infection occurs with high frequency in patients with HIV 
and  HCV  combined  infections  (35%),  signifying  the  common 
modes of transmission of HGV and HCV.
• Among  the  HIV  positive  study  group,  HBsAg  positives  with 
HGV  co-infection  had  higher  mean  CD4  counts,  when 
compared to HBsAg positives without HGV co-infection. There 
was  no  significant  difference  observed  between  the  HCV 
positives with or without HGV co-infection. This implies that the 
presence of HGV RNA is associated with milder HIV status in 
individuals with HIV and HBV combined infection.
• Among  the  HIV  positive  study  group,  HGV  positive  patients 
with  hepatitis  B  and /  or  hepatitis  C co-infections  had higher 
mean ALT levels, when compared to HGV negative individuals. 
This implies that,  presence of HGV RNA was associated with 
severe  hepatitis  in  patients  with  HIV  and   HBV   or  HCV 
combined infections.
• The present  study  throws  light  upon the  co  existence of  HIV 
with Hepatotrophic viruses in a tertiary care center like ours.
• Only very few studies have been performed in India analyzing 
the coexistence of HGV with HIV. Our study can be considered 
as pioneer study in this context. The results aid the central HIV 
programme  implementing  agencies,  especially  in  the  field  of 
ART  to  give  importance  to  hepatitis  G  virus,  along  with 
hepatitis B and hepatitis C viral infections.
ABBREVIATIONS
HIV         – Human Immuno Deficiency Virus
AIDS       – Acquired Immuno Deficiency Syndrome
VCCTC   - Voluntary Confidential Counselling and Testing Centre
HBV       - Hepatitis B virus
HCV         - Hepatitis C virus
HGV           – Hepatitis G virus
ELISA         - Enzyme Linked Immuno Sorbent Assay
RT PCR       – Reverse Transcriptase- Polymerase Chain Reaction
ALT               – Alanine Amino Transferase
HAART            – Highly Active Anti Retroviral Therapy
APPENDIX 
PROFORMA
Name: Address:
PID No:
Age: Occupation:
Sex – Male/Female
Income: <500, 1000-3000, 3000-5000, More than 5000
Marital Status: Married/Unmarried/Widow/Widower/ Separated
Heterosexual/ Homosexual
Sexual Habits – Pre marital / Extra Marital
Contact with Women in Prostitution – Yes/No
Last Contact:
Use of Condom – Yes/No
HISTORY
H/o. STD – Yes/No
Genital Ulcer – Yes/No
Genital Discharge – Yes/No
H/o Lymphadenopathy – Yes/No
Treatment for STD/HIV – Yes/No
Fever – Yes/No Duration – Days/weeks/Months
Loss of Appetite – Yes/No
Weight Loss - <10%, 10-25%, 25-50%, > 50%
Dysphagia – Yes / No Duration – Days/weeks/Months
Fatigue – Yes /No Duration – Days/weeks/Months
Diarrhea – Acute/Chronic
Pain Abdomen – Yes/No
Jaundice – Yes/No
Pulmonary Symptoms – Yes/No
Headache – Yes/No
Seizure – Yes / No
Neurologic deficit – Yes/No
Personal habits – Smoking/Alcohol/Drugs
EXAMINATION
Height Weight
Anemia – Yes/No Lymph Node – Yes/No
Oral Candidiasis – 
Cardiovascular System – Normal/Abnormal
Respiratory System – Normal/Abnormal
Abdomen – Normal /Abnormal
Central Nervous System – Normal / Abnormal
INVESTIGATIONS
TC – DC - Hb–
Platelet Count – ESR –
Liver Function Tests: (Patients on admission)
S. Bilirubin – Total: Direct –
SAP –
SGOT – SGPT –
S.T. Proteins – S. Albumin –
Ultrasonogram –
ELISA
HIV 1 and 2 –
HBs Ag –
Anti Hbs Ag –
HBe Ag (If HBs Ag +ve) –
Anti HCV Ab –
PCR
HGV RNA –
FLOW CYTOMETRY
CD4/ CD8 –
ELISA
All  the  ELISAs  were  performed  by  strictly  following  the 
manufacturer’s testing protocol instructions and results were interpreted 
only when the controls were satisfactory.
 HIV ELISA
 I.MICROLISA
MICROLISA  HIV  test  is  an  enzyme  immunoassay  based  on 
 Indirect  ELISA. Recombinant  proteins gp 41, C terminus of  gp120 for 
HIV-1,  and  gp  36  for  HIV-1  and  HIV-2  representing immunodominant 
epitopes are coated onto microtiter wells .
Test procedure
• 100 µl of the sample diluent was added to A1 well as blank
• 100  µl  of  Negative  Control  was  added to  wells  B1  and C1 and 
100µL  of  Positive  Control  was  to  the  wells   D1,  E1  and  F1 
respectively.
• 100  µl  of sample diluent was added in all  the wells starting from 
G1 followed by the addition of 10 µl of sample from G1.
• Cover seal was applied and incubated for 37°C for 30 min.
• Wells were washed well  with working wash solution according to 
the wash procedure.
•  100  µl  of working conjugate solution was added to all  the wells 
including A1.
• Cover seal was applied and incubated for 37°C for 30 min.
• Wells were washed well  with working wash solution according to 
the wash procedure.
• 100  µl  of  working  substrate  solution  was  added to  all  the  wells 
including A1.
• The  microtitre  plate  was  incubated  at  room  temperature 
( 20-30°C) for 30 min in dark.
• 50 µl of stop solution was added and the absorbance was read at 
450 nm within 30 minutes in ELISA reader after blanking A1.
Validity Criteria
Blank must be < 0.100
Negative control must be  <  0.150
Positive control must be >    0.50
Calculation of results
Cut  off  value  =  Mean  of  Negative  control  +  Mean  of  positive 
control
                                                                 6
II. InTec – HIV ELISA( 3rd generation)
InTec is an ELISA based, double antigens “sandwich” immunoassay, which employs 
a variety of recombinant HIV antigens: some (gp 120/gp41/gp36/p24) immobilized at 
the  bottom  of  microtiter  wells,  and  others  (gp120/gp41/gp36/p24)  coupled  with 
horseradish peroxidase (HRP) as conjugate solution.
Test Procedure
• 50 µl of Positive Control was added to wells B1, C1 and D1. 50µL 
of Negative Control was to the wells  E1, F1 and G1 respectively. 
Well A1 was treated as blank.
• 50 µl of sample was added starting from well H1 .
• 100  µl  of enzyme conjugate working solution was added into all 
the wells except for blank.
•  Cover seal was applied and incubated for 37°C for 60 min.
• Wells were washed well  with working wash solution according to 
the wash procedure.
• 50 µl of color A and 50 µl of color B was added to each well.
• Cover seal was applied and incubated for 37°C for 20 min
• 50  µl  of  2  M  sulfuric  acid  was  added  to  all  the  wells  and  the 
absorbance was read at 450 nm or 450 and 630 nm as reference 
within 30 minutes in ELISA reader.
Validity Criteria
Blank must be <    0.100
Negative control must be  <  0.100
Positive control must be >    0.500
Calculation of results
Cut off value =  Mean of positive control x 0.1 + 0.050
HBV ELISA
I.HBsAg  ELISA 
Hepalisa
HEPALISA  is  a  solid  phase  enzyme  linked immunosorbent 
assay based on the "Direct Sandwich" principle. The microwells are 
coated with Monoclonal antibodies with high reactivity for HBsAg.
      Test Procedure
• 100 µl of Negative Control was added to wells B1 and C1. 100µL 
of Positive Control was to the wells  D1, E1 and F1 respectively. 
Well A1 was treated as blank.
• 100 µl of sample was added in each well starting from G1
• Cover seal was applied and incubated for 37°C for 30 min.
• Wells were washed well  with working wash solution according to 
the wash procedure.
• 100  µl  of  working  enzyme conjugate was added to  all  the wells 
except A1.
• Cover seal was applied and incubated for 37°C for 30 min.
• Wells were washed well  with working wash solution according to 
the wash procedure.
• 100  µl  of  working  substrate  solution  was  added to  all  the  wells 
including A1
• The  microtitre  plate  was  incubated  at  room  temperature 
( 20-30°C) for 30 min in dark.
• 50 µl of stop solution was added and the absorbance was read at 
450 nm within 30 minutes in ELISA reader after blanking A1( use 
of a reference filter of 630nm is preferred).
Validity Criteria
Blank must be < 0.100
Negative control must be 0.005 < NC< 0.150 
Positive control must be >    0.5
Calculation of results
     Cut off value =  Mean of positive control x 0.1 + 0.050
II.HBeAg ELISA
The assay is direct, non competitive test based on the use of 
polystyrene microwells  coated with  mouse monoclonal  antibodies to 
Hepatitis B e antigen.
Test Procedure
• 50  µl  of  incubation buffer  was added to all  the wells,  except for 
the blank well. Dispense reagents into the strip wells according to 
the following scheme, leaving an empty well for the blank.
Reagents No of Replicates Volume
Calibrator
Negative control
Positive control
Samples
3
1
1
1
100 µl
100 µl
100 µl
100 µl
• The plate was incubated for 2 hours at 37° C 
• Wells were washed well  with working wash solution according to 
the wash procedure.
• 100  µl  of  working  enzyme  tracer  was  added  to  all  the  wells, 
except A1
• The plate was incubated for 1 hour at 37° C 
• Wells were washed well  with working wash solution according to 
the wash procedure.
• 100  µl  of  working  substrate  solution  was  added to  all  the  wells 
including A1
• The  microtitre  plate  was  incubated  at  room  temperature 
( 20-30°C) for 30 min in dark.
• 100  µl  of stop solution was added and the absorbance was read 
at 450 nm within 30 minutes in ELISA ( use of a reference filter of 
630nm is preferred).
Validity Criteria
Blank must be 0.000 < BLK<  0.150  
Calibrator must be –0.020 < Cal mean < 0.120
Negative control must be -0.020 < NC< 0.120 
Positive control must be 0.500 < PC < 2.500
PC – NC > 0.450
Calculation of results
        Cut- off value = Cal mean + 0.060
III. ANTI HBS ELISA
It  is  quantitative\  qualitative  ,direct,  non  competitive,  sandwich 
assay.  Wells  are  coated  with  human  HBsAg   to  detect  anti  HBs  from 
sample  or  calibrator.  Enzyme  tracer  is  human  HBsAg  conjugated  to 
horseradish  peroxidase  (HRP).The  presence  of  anti  HBs  allows  the 
enzyme  tracer  to  bind  to  the  solid  phase.  The  enzyme  activity  is 
therefore  proportional  to  the  concentration  of  anti  HBs  present  in  the 
samples or calibrators.
Test procedure
• 100  µl  of  incubation  buffer  was  added  into  all  wells  except  for 
blank A1.
• 100 µl of Negative control was added to the well B1 and 100 µl of 
Calibrators 1, 2, 3, 4 were added to wells C1, D1, E1 and F1.
• 100 µl of sample was added starting from G1.
• Cover  seal  was  applied  and  incubated  for  37°C for  2  hrs  + 10 
min.
• Wells were washed well  with working wash solution according to 
the wash procedure
• 100  µl  of  working  enzyme  tracer  was  added  to  all  the  wells, 
except A1.
• Cover seal was applied and incubated for 37°C for 1 hr + 5 min.
• Wells were washed well  with working wash solution according to 
the wash procedure
• 100  µl  of  working  substrate  solution  was  added to  all  the  wells 
including A1
• The  microtitre  plate  was  incubated  at  room  temperature 
( 20-30°C) for 30 + 2 min in dark.
• 200  µl  of  blocking  reagent  was  added  to  all  the  wells  and  the 
absorbance was read at 405/ 630 nm within 30 minutes in ELISA 
( use of a reference filter of 630nm is preferred).
Validity Criteria
Negative control must be NC <  0.100 
Calibrator 1  must range between  0.035 < Cal 1 < 0.300
The ratio of Calibrator 1 to negative control must be  Cal 1 / NC > 2.0
The ratio of Calibrator 4 to Calibrator 3 must be Cal 4 / Cal 3 > 1.2
Calculation of results
The absorbance value at  405 /  630 nm for  each calibrator  were 
ploted in log- log 
co-ordinates  on  the  ordinate  (  Y  axis)  as  a  function  of  the 
concentration of anti-  HBs antibody expressed as IU/L on the abscissa 
(X axis).
A calibration curve is obtained. Directly from the calibration curve, 
read the anti- HBs concentration of each sample expressed as IU/L.
HCV ELISA
Zhongshan HCV
It  is  a  third  generation  enzyme  immunoassay  for  the  qualitative  determination  of 
antibody to hepatitis C virus in human serum/plasma.
Test procedure
• 100  µl  of  the  sample  diluent  was  added to  wells  A1 and B1 as 
blank control.
• 100 µl of Negative Control was added to wells C1 and D1 . 100µL 
of Positive Control was to the wells  E1 and F1 respectively.
• 100  µl  of sample diluent was added in all  the wells starting from 
G1 followed by the addition of 10 µl of sample from G1.
• Cover seal was applied and incubated for 37°C for 30 min.
• Wells were washed well  with working wash solution according to 
the wash procedure
• 50  µl  of  conjugate  was  added  to  all  the  wells  except  for  blank 
control.
• Cover seal was applied and incubated for 37°C for 20 min.
• Wells were washed well  with working wash solution according to 
the wash procedure.
• 50  µl  of substrate solution A and 50  µl  of substrate solution B is 
added to each well, including blank.
• Cover seal was applied and incubated for 37°C for 10 min in dark.
• 50  µl  of  stop  solution  is  added  to  all  the  wells  including  blank 
control.
• The  absorbance  was  determined  for  each  well  at  450  nm  with 
ELISA reader.
Validity Criteria
Blank must be < 0.100
Negative control must be  <  0.100
Positive control must be >    0.600
Difference between the mean of positive and negative control 
must be >    0.500
Calculation of results
Cut off value =  0.15 + mean absorbance of negative control.
DETERMINATION OF CD4 / CD8 COUNT BY FLOW CYTOMETRY
CD4 and CD8 counts were determined with the help FACS count 
system ( Becton Dickinson Immunocytometry systems).
Control runs were set up each time when the instrument is run, or 
when a new lot of reagents were used.
One reagent tube pair was used for each patient.
TEST PROCEDURE
• One reagent tube pair is labeled with patient accession number or 
number that identifies the tube of blood.
• The pair was vortexed upside down for 5 secs and upright for 5 
secs.
• The reagent tube pair was opened with the coring station.
• The patients whole blood sample was mixed well by inverting the 
tube 5 times.
• 50 µl of the whole blood was pipetted into each of the two reagent 
tubes. The pipettes were changed between tubes.
• The tubes were capped and vortexed upright for 5 secs.
• The  tubes  were  incubated  for  60  to  120  minutes  at  room 
temperature                    ( 20 to 25 °  C).
• The tubes were then uncapped, and 50 µl of fixative solution was 
added  into  each  of  the  two  reagent  tubes.  The  pipettes  were 
changed between tubes.
• The  reagent  tubes  were  recapped  with  new caps  and  vortexed 
upright for 5 secs.
• The  tubes  were  run  on  the  FACS  count  instrument  and  CD4  / 
CD8 results were obtained.
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